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Abstract The Rotterdam Study is a prospective cohort
study ongoing since 1990 in the city of Rotterdam in The
Netherlands. The study targets cardiovascular, endocrine,
hepatic, neurological, ophthalmic, psychiatric, dermato-
logical, otolaryngological, locomotor, and respiratory dis-
eases. As of 2008, 14,926 subjects aged 45 years or over
comprise the Rotterdam Study cohort. The findings of the
Rotterdam Study have been presented in over 1200
research articles and reports (see www.erasmus-epidemiol
ogy.nl/rotterdamstudy). This article gives the rationale of
the study and its design. It also presents a summary of the
major findings and an update of the objectives and
methods.
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Introduction
The Rotterdam Study was designed in the mid-1980s as a
response to the demographic changes that were leading to
an increase of the proportion of elderly people in most
populations [1]. It was clear that this would produce a
strong rise in elderly people living with diseases, as most
diseases cluster at the end of life, and that to discover the
causes of diseases in the elderly one would have to study
risk factors of those diseases [2]. A major approach to
finding causes is the prospective follow-up study, which
has proven quite effective in finding causes of heart disease
and cancer.
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The design of the Rotterdam Study
The design of the Rotterdam Study is that of a prospective
cohort study among, initially, 7983 persons living in the
well-defined Ommoord district in the city of Rotterdam in
The Netherlands (78 % of 10,215 invitees). They were all
55 years of age or over and the oldest participant at the
start was 106 years [3]. The study started with a pilot phase
in the second half of 1989. From January 1990 onwards
participants were recruited for the Rotterdam Study. Fig-
ure 1 gives a diagram of the various cycles in the study. In
In 2000, 3011 participants (out of 4472 invitees) who had
become 55 years of age or moved into the study district
since the start of the study were added to the cohort. In
2006 a further extension of the cohort was initiated in
which 3932 subjects were included, aged 45–54 years, out
of 6057 invited, living in the Ommoord district. By the end
of 2008, the Rotterdam Study therefore comprised 14,926
subjects aged 45 years or over [4, 5]. The overall response
figure for all three cycles at baseline was 72.0 % (14,926 of
20,744).
The participants were all examined in some detail at
baseline. They were interviewed at home (2 h) and then
had an extensive set of examinations (a total of 5 h) in a
specially built research facility in the centre of their dis-
trict. These examinations focused on possible causes of
invalidating diseases in the elderly in a clinically state-of-
the-art manner, as far as the circumstances allowed. The
emphasis was put on imaging (of heart, blood vessels, eyes,
skeleton and later brain) and on collecting body fluids that
enabled further in-depth molecular and genetic analyses.
These examinations were repeated every 3–4 years in
characteristics that could change over time. And so there
were examination cycles from 1990 to 1993, from 1993 to
1995, from 1997 to 1999, from 2000 to 2001, from 2002 to
2004, from 2004 to 2005, from 2006 to 2008, from 2009 to
2011, from 2011 to 2012, from 2012 to 2014, from 2014 to
2015, and from 2015 onwards (Fig. 1). In January 2016 the
fourth examination cycle for the second cohort (RS-II-4)
will be finished. In February 2016 a fourth cohort will be
established. The age range for this new cohort is predom-
inantly 40–55 years, the anticipated number of participants
is 4000.
The participants in the Rotterdam Study are followed for
a variety of diseases that are frequent in the elderly:
coronary heart disease, heart failure and stroke, Parkinson
disease, Alzheimer disease and other dementias, depression
and anxiety disorders, macular degeneration and glaucoma,
respiratory diseases, liver diseases, diabetes mellitus,
osteoporosis, dermatological diseases and cancer.
The Rotterdam Study has been approved by the insti-
tutional review board (Medical Ethics Committee) of the
Fig. 1 Diagram of examination cycles of the Rotterdam Study (RS).
RS-I-1 refers to the baseline examination of the original cohort (pilot
phase 07/1989–12/1989; cohort recruitment 01/1990–09/1993). RS-I-
2, RS-I-3, RS-I-4, RS-I-5, and RS-I-6 refer to re-examinations of the
original cohort members. RS-II-1 refers to the extension of the cohort
with persons in the study district that became 55 years since the start
of the study or those of 55 years or over that migrated into the study
district. RS-II-2, RS-II-3, and RS-II-4 refer to re-examinations of the
extension cohort. RS-III-1 refers to the baseline examination of all
persons aged 45 years and over living in the study district that had not
been examined already (i.e., mainly comprising those aged
45–60 years). RS-III-2 refers to the first re-examination of this third
cohort. Examination RS-I-4 and RS-II-2 were conducted as one
project and feature an identical research program. Similarly, exam-
inations RS-I-5, RS-II-3, and RS-III-2 share the same program items.
Also, examinations RS-I-6 and RS-II-4 are conducted as one project.
RS-IV-1 refers to the baseline visit of a new cohort, to be established
in February 2016
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Erasmus Medical Center and by the review board of The
Netherlands Ministry of Health, Welfare and Sports. The
approval has been renewed every 5 years, as well as with
the introduction of major new elements in the study (e.g.,
MRI investigations).
In the remainder of this article the objectives and major
findings will be presented with an update of the research
methods for cardiovascular diseases, dermatological dis-
eases, endocrine diseases, liver diseases, neurological dis-
eases, ophthalmic diseases, psychiatric diseases,
respiratory diseases, as well as for genetic and biomarker
studies and for pharmaco-epidemiologic studies. For rele-
vant recent EJE references see [6–28].
Cardiovascular diseases
Objectives
Research on the epidemiology of cardiovascular disease
focuses on the etiology, prognosis, and prediction of car-
diovascular disorders (including coronary heart disease,
stroke, heart failure) diabetes mellitus and metabolic syn-
drome. The main emphasis is on prevention and manage-
ment of a first cardiovascular event but prevention of
secondary events is also an area of interest. Putative risk
factors include five groups: lifestyle factors, endocrine
factors, factors involved in hemostasis, inflammation and
endothelial function, metabolomic factors and genetic
factors. We have five specific focused themes:
1. Lifestyle: focused on evaluating the role of lifestyle
factors (including nutrition, physical activity, sleep and
smoking) in maintaining cardiovascular health as well as
the interactions that lifestyle factors might have on other
factors (e.g. genes, epigenetic marks and medications).
2. Biomarkers and genes: aimed to identify relevant
biomarkers for the identification of novel mechanisms
of disease. These incorporate both molecular and
genetic factors together with their potential interac-
tions. Genomics, epigenetic marks and metabolomics
play a key role.
3. Prediction and women’s cardiovascular health: aimed
to improve the identification of individuals at increased
risk of developing cardiovascular disease in order to
point out windows of opportunities that could permit
early preventive interventions and personalised care. A
special focus is given to evaluating specific factors and
formulating targeted strategies to prevent cardiovas-
cular disease in women.
4. High risk: focused on predictors and prognosis of
chronic cardiovascular conditions, like heart failure,
pulmonary hypertension, and atrial fibrillation.
5. Imaging: this work theme aims to identify the contri-
bution that new technologies can provide to the
maximum benefit of early diagnosis and accurate
prognosis. Major focus is on non-invasive assessment
of atherosclerosis to improve the understanding of the
atherosclerotic process and the prediction of cardio-
vascular disease, including measurement of coronary
calcification with electron-beam and multi-detector CT
(MDCT) and carotid plaque characterization by MRI.
Major findings
Anthropometrics and cardiovascular disease
We evaluated different anthropometric measures, including
body mass index, waist circumference, waist to height
ratio, waist to hip ratio and a body shape index in associ-
ation with all-cause, cardiovascular and cancer mortality.
We have shown that among different anthropometric
measures, body shape index was strongly associated with
the risk of all-cause, cardiovascular and cancer mortality
[29]. Within the European Network for Genetic and
Genomic Epidemiology (ENGAGE) consortium, using a
mendelian randomization approach, we found that adi-
posity, as indicated by body mass index, has a causal
relationship with coronary heart disease, heart failure and
for the first time, ischemic stroke [30]. Also, there were
age- and sex-specific causal effects of adiposity on car-
diovascular risk factors, including cholesterol, blood pres-
sure, fasting levels of insulin and C-reactive protein [31].
Comparison of guidelines
The new American College of Cardiology/American Heart
Association (ACC/AHA) guidelines introduced a new
cardiovascular (CVD) prediction model and lowered the
threshold for treatment with statins to a 7.5 % 10-year hard
atherosclerotic cardiovascular disease (ASCVD) risk.
Using 4854 asymptomatic participants from the popula-
tion-based Rotterdam Study, we determined the implica-
tions of the new ACC/AHA guideline’s treatment threshold
and risk prediction model and compared it with the Adult
Treatment Panel III (ATP-III), and the European Society of
Cardiology (ESC) guidelines. We showed that proportions
of individuals eligible for treatment with statins differed
substantially among the 3 guidelines [32]. The ACC/AHA
guideline would recommend statins for nearly all men and
two-thirds of women, proportions exceeding those with the
ATP-III or ESC guidelines. All risk prediction models
underlying the 3 guidelines provided poor calibration and
moderate to good discrimination in our population. To
facilitate better clinical decision making, improving risk
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predictions and setting appropriate population-wide
thresholds are necessary.
Women’s health
Women experience multiple health issues throughout their
life course differently from men. Therefore, attention to
women’s health is important in all stages in life. To
improve women’s quality of life and guarantee a long-
lasting and active role for women in society, prevention of
chronic diseases and disability is a key aspect. Our focus,
therefore, in the women’s health group is on the major
health issues for peri- and post-menopausal women, their
risk factors, and prevention strategies [33].
As menopausal health is a crucial aspect in healthy and
successful aging, we aimed to characterize a concept for
healthy menopause. We conceptualized healthy menopause
as a dynamic state, following the permanent loss of ovarian
function, which is characterized by self-perceived satis-
factory physical, psychological and social functioning,
incorporating disease and disability, allowing the attain-
ment of a woman’s desired ability to adapt and capacity to
self-manage. Conceptualization of healthy menopause
serves as a crucial step in improvement of health in
menopausal women, allowing for adapting adequate pre-
ventive and treatment strategies [34].
Although cardiovascular disease (CVD) remains one of
the leading causes of death and disability for both men and
women, our research underscores considerable sex differ-
ences in the occurrence of the various manifestations of
CVD. Using the long term follow-up from the prospective
population based Rotterdam Study, we showed that despite
similar lifetime risks of CVD at age 55 for men and
women, considerable differences in the first manifestation
exist. Men are more likely to develop coronary heart dis-
ease as a first event, while women are more likely to have
cerebrovascular disease or heart failure as their first event,
although these manifestations appear most often at older
ages [35]. Since strategies for prevention of stroke and
heart failure might differ from strategies for prevention of
coronary heart disease, to devise a sex-tailored primary
prevention program, knowledge about the first manifesta-
tion of diseases is important.
Heart failure and atrial fibrillation
The Rotterdam Study enabled accurate assessment of the
incidence and lifetime risk of heart failure and atrial fib-
rillation in an elderly population [36–38]. It was shown that
inflammation and resting heart rate is associated with risk
of heart failure [39, 40]. In addition we identified several
new risk factors of atrial fibrillation. We found that
markers of generalized atherosclerosis in persons without a
history of myocardial infarction or angina were associated
with a higher risk of atrial fibrillation [41]. Furthermore,
high-normal thyroid function [42] and higher levels of
dehydroepiandrosterone sulfate, a precursor in the biosyn-
thetic pathway of androgenic and estrogenic sex hormones
were associated with incidence of atrial fibrillation [43]. In
collaboration with several community-based prospective
studies we were able to develop a prediction model for
atrial fibrillation, only using variables that are routinely
collected in primary care settings [44]. In a large collabo-
rative study as part of the CHARGE consortium, we
investigated the genetic variation responsible for 6 traits
related to cardiac structure and function. We found two
replicated loci for left ventricular dimension and 5 repli-
cated loci for aortic root size [45]. Another topic of interest
was the search for genetic determinants of several rhythm
and conduction disturbances on the ECG, notably RR-in-
terval, QRS duration, and QT(c)-interval, PR-interval, as
well as atrial fibrillation and sudden cardiac death. For
example, we identified several new loci for PR interval
[46], heart rate [47], and atrial fibrillation [48, 49] in meta-
analyses from the CHARGE consortium.
Cardiovascular risk factors and prediction
Endocrine, inflammatory and hemostatic factors and risk of
coronary heart disease were addressed in several studies.
Subclinical hypothyroidism was an independent risk factor
of atherosclerosis and myocardial infarction in older
women [50]. In a recent study, we compared the change in
the accuracy of risk predictions when newer risk markers,
representative of various pathophysiologic pathways, were
added to the established clinical risk predictors. Among the
biomarkers, improvements in coronary heart disease risk
prediction were most significant with the addition of
amino-terminal pro-B-type natriuretic peptide (NT-
proBNP) [51, 52]. Furthermore, plasma C-Reactive protein
(CRP) and lipoprotein-associated phospholipase A2 (Lp-
PLA2) activity were independent predictors of coronary
heart disease [53, 54]. Earlier findings included the asso-
ciation of tissue plasminogen activator (TPA) with incident
coronary heart disease [55]. Using a comprehensive bio-
marker assay, we analysed multiple markers of inflamma-
tion among 800? individuals with incident coronary heart
disease [56]. We identified EN-RAGE as a novel bio-
marker for incidence of coronary heart disease, indepen-
dent of established risk factors and inflammatory markers,
such as C-reactive protein [56]. With respect to the pre-
diction of coronary heart disease, EN-RAGE improved
prediction significantly indicating that EN-RAGE might be
useful in CHD prediction [56]. Recently, we developed and
validated a coronary heart disease prediction model tai-
lored for the aging population based on competing risk
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methodology [57]. Also, we have shown that the non-lab-
oratory based model, based on body shape index, could
predict risk of cardiovascular disease as accurately as one
that relied on laboratory-based values among men [58].
Non-invasive measures of atherosclerosis
Multiple studies focused on the predictive value of non-
invasive measures of atherosclerosis for risk of coronary
heart disease. Strong associations with risk of coronary
heart disease were found for carotid intima-media thick-
ness [59], pulse wave velocity [60], and coronary calcifi-
cation as assessed by electron-beam CT [61]. The relatively
crude measures directly assessing plaques in the carotid
artery and abdominal aorta predict coronary heart disease
equally well as the more precisely measured carotid intima-
media thickness [62]. In persons at intermediate risk of
cardiovascular disease, coronary artery calcium provided
the best increment in coronary heart disease risk prediction
and stratification (to reclassify persons into more appro-
priate coronary risk categories) [51, 63, 64]. The burden of
coronary calcification also provides incremental predictive
information for heart failure, but nor for cerebrovascular
disease [65, 66].
Genetic studies
Genetic studies included candidate gene studies [67] and
more recently genome-wide association studies of clinical
disease and risk factor phenotypes. So far we have con-
tributed to more than 100 Genome-wide association
(GWA) studies in the field of cardiovascular disease. These
GWA studies are primarily conducted in the framework of
the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium [68, 69] however in
many instances we include further studies. We identified 3
genetic loci associated with uric acid concentration and
gout [70]. Three loss-of-function variants in HAL gene
were found to associate with histidine levels [71] but not
with coronary heart disease. We also identified a significant
association between the UMOD gene which encodes
Tamm-Horsfall protein and chronic kidney disease [72].
We found four genes for systolic blood pressure, six for
diastolic blood pressure and one for hypertension [73–75].
We found multiple loci that influenced erythrocyte phe-
notypes in the CHARGE Consortium [76]. In a meta-
analysis in more than 80,000 individuals from 25 studies,
we identified 18 loci for CRP levels. The study highlighted
immune response and metabolic regulatory pathways
involved in the regulation of chronic inflammation [77].
Novel associations of 12 low-frequency exonic variants
with plasma levels of factor VII, factor VIII, and von
Willebrand factor were also detected [78, 79]). The
association with these variants was independent of the
previously identified common variants associated with
these traits, and the effect sizes were larger. We performed
the first GWA study of ADAMTS13 activity, identifying
independent associations with three common variants at the
ADAMTS13 locus, as well as one common variant at the
SUPT3H locus [80]. Additionally, we used a genotyping
array focused on rare exonic variants to identify three
independent rare variants in the ADAMTS13 gene associ-
ated with ADAMTS13 activity [80]. We have also identi-
fied genetic loci associated with the measures of subclinical
atherosclerosis burden. Our genome-wide association
studies on the 3 measures of subclinical atherosclerosis
identified several new genetic loci [81–83]. We have
contributed to GWA studies on coronary artery disease [84,
85]. Also, we found that 152 known coronary heart disease
SNPs improved the prediction of prevalent but not incident
coronary heart disease. This difference may be explained
by biases related to the use of prevalent rather than incident
coronary heart disease in genome-wide association studies
[86]. In addition, by using genome-wide methylation data,
we found an effect of tobacco smoking on DNA methy-
lation of 12 coronary artery disease-related genes, and thus
providing novel insights in the pathways that link tobacco
smoking to risk of coronary artery disease [87].
Thus far, a large number of genetic variants have been
identified by GWAS that contribute to the induction and
development of cardio-metabolic diseases. Nevertheless,
the vast majority of the identified variants map to the non-
coding regions of genome that their biological relevant to
the disease remain unclear. Non-coding RNAs play regu-
latory roles in various biological processes and cellular
contexts. We identified a number functional variants in
microRNA-genes and microRNA binding sites on the
3U´TR of coding genes that affect miRNA gene regulation
and explain some of the observed associations from GWAS
of cardio-metabolic phenotypes [88–90].
Nutrition and lifestyle
We found that subjects who had fish intake of more than
19 g/day had a significantly lower prevalence of
mild/moderate coronary calcification [91]. Also, we found
that an increase of 50 g in processed meat was associated
with increased CRP levels [92]. In addition to this, the
intake of processed meat was associated with a higher risk
of type 2 diabetes which was independent of CRP levels
[92]. The dietary intake of fatty acids and its relation with
CRP levels was studied as well. We found that higher
intake of total PUFAs was associated with lower CRP
levels and the intake of n-6 PUFAs were inversely asso-
ciated with CRP [93]. We did not observe an association
between n-3 PUFAs or n-3:n-6 PUFA ratio and CRP.
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Likewise, we studied whether dietary proteins, amino acids
and acid load were associated with the risk of hypertension.
It appeared that these factors were not a major determinant
of the risk of hypertension in the Rotterdam Study [94–96].
On the other hand, we found that higher vitamin D con-
centrations were associated with lower prevalence of
metabolic syndrome. In particular, adequate levels of
vitamin D were associated with more beneficial HDL,
triglycerides, waist circumference and serum glucose levels
[97]. We did not observe an association between vitamin D
and atrial fibrillation [98]. Also, we found no association
between coffee consumption and incident dementia [99].
High-fat dairy was inversely related to fatal stroke, but not
to incident stroke. Total dairy consumption or dairy sub-
groups (e.g. milk, low-fat dairy) were not associated with
the occurrence of CVD events [100]. We investigated
relationship of epicardial fat volume with atherosclerotic
calcification volume and found that larger epicardial fat
volume was related to coronary and extracranial carotid
artery calcification volume in males only [101]. As part of
the CHANCES consortium, we found that adherence to a
healthy diet according to the WHO was associated with
greater longevity [102].
Besides main effects of nutrition, we studied gene-nu-
trient interactions. We found that dietary vitamin E intake
may modulate the relation of SIRT1 genetic variants with
body mass index [103]. Also, we studied the modification
of magnesium, whole grain and a healthy diet score on
fasting glucose and insulin by SNPs related to fasting
glucose and insulin as part of the CHARGE consortium
[104–106]. Furthermore, low dietary carbohydrate intake
and normal sleep duration were found to ameliorate car-
diometabolic abnormalities conferred by common circa-
dian-related genetic variants [107].In addition to nutrition,
we also investigated lifestyle factors and found that there is
no association between positive psychological well-being
and incidence of cardiovascular disease [108]. We did find
an association between clinical heart failure and poor sleep
quality over time, but did not find an association between
cardiac dysfunction (measured by echocardiography) and
sleep quality [109].
Methods update
Clinical follow-up
Information on clinical cardiovascular outcomes is col-
lected through an automated follow-up system. The follow-
up system involves linkage of the study base to digital
medical records from general practitioners in the study area
and subsequent collection of letters of medical specialists
and discharge reports in case of hospitalisation. With
respect to the vital status of participants, information is also
obtained regularly from the municipal health authorities in
Rotterdam. After notification, cause and circumstances of
death are established by questionnaire from the treating
physicians. Clinical cardiovascular outcomes are adjudi-
cated according to established definitions based on inter-
national guidelines by study physicians and medical
specialists in the field affiliated with the Rotterdam Study.
Methods of follow-up data collection, adjudication of
events, and definitions of cardiovascular end points have
been described in detail previously in this journal [110].
Systematic follow-up data collection is done for the
occurrence of cardiovascular mortality, coronary heart
disease (including coronary death, myocardial infarction,
and coronary revascularization procedures), heart failure,
atrial fibrillation, and sudden cardiac death [110]. Diabetes
mellitus is defined based on guidelines of the American
Diabetes Association and the World Health Organization.
We defined incident diabetes as fasting plasma glucose
level C7.0 mmol/L, or the use of oral antidiabetic medi-
cation or insulin, or treatment by diet and registered by a
general practitioner as having diabetes.
Cardiovascular risk factors
Besides traditional cardiovascular risk factors, five major
groups of putative risk factors for cardiovascular conditions
are examined. The first group are lifestyle factors, includ-
ing dietary factors, physical activity, smoking, sleep and
vitamin D (as described above). The second are endocrine
factors, including diabetes, sex hormones, thyroid gland
and adrenal gland hormones and natriuretic peptides (e.g.
[42, 43, 50–52]). The third group comprises factors
involved in hemostasis, inflammation and endothelial
function (e.g. [53, 111, 112]). The fourth group covers
genetic factors. In addition to the candidate gene approach,
studies are more recently conducted through the genome-
wide association approach (e.g. [45–49, 70, 72–77, 81–85,
104–106, 111]). In genome-wide association studies, data
from the Rotterdam Study are often combined with those
from other studies in the context of the large collaborative
CHARGE consortium [68, 69]. Within the fifth group we
are applying both proton nuclear magnetic resonance (1H
NMR) and mass spectrometry (MS) for metabolic profiling
in 2000 participants of the Rotterdam Study including
nearly 200 incident cases of coronary heart disease. Fur-
thermore, in this context, special attention has been given
to the contribution of different risk factors in relation to
cardiovascular disease in women. Data has been collected
to evaluate the impact of specific periods of potential
vulnerability across a woman’s lifespan; menarche, preg-
nancy, and menopause. Also, DNA methylation can regu-
late gene expression without altering the underlying DNA
sequence and is now emerging as a promising molecular
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strategy for risk stratification for complex disease, includ-
ing cardiovascular disease. Using the Illumina Infinium
HumanMethylation450 array, we have generated DNA
methylation profiles of *480,000 CpG sites in In *1000
samples of the RS-III.
Non-invasive measures of atherosclerosis
At baseline and follow-up examinations, ultrasonographic
assessments of carotid intima-media thickness and carotid
plaques were conducted in all participants [59]. At these
examinations, also measurements of the ankle-brachial
index and aortic calcification (on X-rays of the lumbar
spine) were obtained [62]. Carotid–femoral pulse wave
velocity, a measure of aortic stiffness, was measured in all
participants of RS-I-3, RS-II-1, and RS-III-1 with an
automatic device [60]. Measurements of coronary calcifi-
cation by electron-beam CT and more recently by MDCT
were conducted from 1997 onwards in RS-I and RS-II [61],
[63]. From 2003 to 2006, MDCT was used to also quantify
calcification in the aortic arch and carotid arteries in RS-I
and RS-II. Measurement of carotid plaque components
using MRI was done from 2007 to 2012 in all participants
from RS-I, RS-II and RS-III with carotid wall thickening
on conventional carotid ultrasound. Repeated MRI mea-
sures over time were obtained in RS-I and RS-II.
Electrocardiographic, echocardiographic and other
ultrasound measurements
At every exam, a 12-lead 10-s resting ECG is made and
processed by the Modular ECG Analysis System
(MEANS) to obtain a series of ECG measurements [113].
Abdominal aortic diameters were measured by ultrasound
at RS-I-1, and from 2002 (RS-I-4) onwards in all three
Rotterdam Study cohorts. Also from 2002 onwards (RS-I-
4), repeated echocardiographic measurements are con-
ducted of structural and functional left heart parameters
[114]. From 2009 (RS-I-5) onwards, measurements of
structure and function of the right heart are also collected,
including estimates of pulmonary artery pressure. In the
same round a 3-min resting ECG was measured in all
participants.
Nutrition and lifestyle
Nutritional data has been collected in RS-I-1, RS-I-5, RS-
II-1, RS-II-3 and RS-III-1 by using semi quantitative food
frequency questionnaires (FFQ). In RS-I-1 and RS- II-1,
participants completed a checklist about foods and drinks
they had consumed at least twice a month during the pre-
ceding year and a standardized interview using a validated
170-item semi-quantitative FFQ [115]. In RS-I-5, RS-II-3
and RS-III-I, a more comprehensive FFQ was used during
the visits as described in detail previously [116–119].
Development and processing of nutrition data is being
performed in close collaboration with the Department of
Human Nutrition, Wageningen University, the Nether-
lands. In RS-I-III, RS-I-5, RS-II-I-3 and RS-III-I, physical
activity data was assessed by means of an adapted version
of the Zutphen Physical Activity Questionnaire and the
LASA Physical Activity Questionnaire [120–122]. The
questionnaire contained questions on walking, cycling,
gardening, diverse sports, hobbies and on housekeeping.
According to time spent in light, moderate and vigorous
activity, metabolic equivalents of task were calculated.
Furthermore, we are implementing objective measurement
of physical activity with triaxial accelerometers in all
participants.
For additional EJE references concerning cardiovascular
disease see [123–182].
Dermatological diseases
Objectives
Dermatoepidemiologic research in the Rotterdam Study
focuses on the frequency of the most common skin con-
ditions as well as on genetic and environmental factors
associated with these skin diseases. The emphasis is on
cutaneous malignancies such as basal and squamous cell
carcinomas (BCC and SCC, respectively) and their pre-
cursor lesions (actinic keratosis), inflammatory dermatoses
such as eczema and psoriasis, and varicose veins. Also, we
examine the frequency and determinants including genetics
and environmental exposures of skin aging (pigmentation,
wrinkling and photodamage) and other visible traits in
collaboration with the department of Genetic Identification.
Recently, we have introduced optic measures of UV
exposed and non-exposed to assess whether they can
function as biomarkers of skin and internal diseases.
Methods
In 2010, dermatology studies were introduced in the Rot-
terdam Study. To the home interview several items have
been added questioning ultraviolet light exposure, history
of (personal and familial) psoriasis, history of skin cancer,
the diagnostic criteria of British Association of Dermatol-
ogy for atopic eczema, adjusted diagnostic criteria for
psoriatic arthritis. More recently, items on skin care and
seborrheic dermatitis/dandruff were added.
A full body skin examination by physicians trained in
dermatology with a focus on the most common skin dis-
eases is the core contribution of dermatology. The clinical
The Rotterdam Study: 2016 objectives and design update 667
123
presence and extent of specific skin diseases (i.e., actinic
keratosis, malignancies, psoriasis, seborrheic dermatitis,
xerosis, hand and flexural eczema, alopecia, and signs of
chronic venous insufficiency based on the ‘C’ of the CEAP
classification) at time of examination is assessed in a
standardized fashion. Other dermatological diseases will
just be noted.
The extent of skin aging as a global score and broken
down in different aspects such as wrinkling, pigmentary
spots, and teleangiecatsia are scored using a validated
photonumeric scales and computer algorithms. The Nor-
wood–Hamilton classification and the Ludwig classifica-
tion is used for male and female pattern hair loss,
respectively. Fully standardized 3-dimensional pho-
tographs (Premier 3dMDface3-plus UHD, Atlanta, USA)
of the face are taken to further assess skin characteristics
including sagging, wrinkling at different sites, teleangiec-
tasia and pigmented spots. The colour of the facial skin and
at the inner side of the upper arm are measured using a
spectrophotometer (Konica Minolta Sensing, spectropho-
tometer CM-700d, Singapore). Recently, we have intro-
duced optic measures of UV exposed and non-exposed skin
such as relectance and fluorescence spectroscopy including
the AGE reader.
As for other cancers, pathology data of the cutaneous
malignancies is obtained from linkage to the national
cancer registry and the Dutch pathology database
(PALGA). In a further attempt to identify cohort members
with psoriasis, medical files and dispenses at pharmacies
have been investigated resulting in over 350 psoriasis
cases.
In 2016, we aim to start collecting skin microbiome in a
randomized manner among all participants. For selected
skin diseases such as eczema, rosacea, seborrheic der-
matosis and psoriasis the affected skin will be sampled as
well.
Major findings
In the first follow-up study including the skin examinations
of more than 2000 cohort members, showed that actinic
keratosis is very common in this elderly population (AK
prevalence was 49 % for men and 28 % for women) [183].
After adjusting for other factors, baldness in men was
associated with a strongly increased risk of actinic
keratosis.
A recent update yielded more than 1500 participants
with a history of BCC, 450 with a SCC and 150 with a
melanoma. We have demonstrated that approximately
30 % of people with a BCC develop multiple tumors with
5 years and have developed a prediction model to identify
these high risk patients. A first genetic analysis could not
confirm any of the existing BCC polymorphisms to be
associated with the development of multiple BCC [184]. In
collaboration with researchers from the Nurses Health
Study, Framingham Heart Study and deCODE, the asso-
ciation between common genetic variants and these skin
cancers is currently being examined.
Recently, we have presented the first GWAS on actinic
keratosis [185]. Several skin color genes such as IRF4,
MC1R, ASIP and BCN2 were significantly associated with
these premalignant skin lesions independently from skin
color.
In a candidate gene study in almost 6000 people, we
confirmed known and identified new variants associated
with digital skin colour extraction. Of the two new skin
color genes, the genetic variants in UGT1A were signifi-
cantly associated with hue and variants in BNC2 were
significantly associated with saturation [186]. In the
International Visible Trait Genetics Consortium, we iden-
tified novel pigmentation genes confirmed by functional
follow up [187]. Several pigmentation genes were also
significantly associated with the presence of pigmented
facial spots in a GWAS [185].
The psoriasis patients within the Rotterdam Study have
predominantly mild disease. The distribution of subclinical
artherosclerosis measures as well as the cardiovascular
events were comparable between the 262 psoriasis patients
and the reference population [188]. However, psoriasis
patients were significantly more likely to have signs of
nonalcoholic fatty liver disease based on ultrasonography
than their controls after adjusting for potential confounders
[189]. Moreover, psoriasis patients were more likely to
have liver fibrosis than controls comparing Fibroscan data
[190].
Endocrine and locomotor diseases
Objectives
The main objective of the programme of endocrine and
locomotor epidemiology research is to study frequency and
etiology of major disorders of the endocrine glands (pitu-
itary, reproductive, thyroid, parathyroid, adrenal, and
neuro-endocrine pancreas) and the musculoskeletal system
and their risk factors. These include diabetes mellitus,
osteoporosis, osteoarthritis, reproductive traits (fertility,
age-at-menopause), and hypo- and hyper-thyroidism. The
evaluation of risk factors for the above mentioned condi-
tions includes serum measurements (such as classical
hormones and other endocrine molecules), imaging of
bones and joints by DXA, X-ray and pQCT, measuring
muscle strength, and genetic determinants of endocrine
diseases and traits. In addition, consequences of these
endocrine disorders are studied in relation to aging related
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diseases, including cardiovascular disease, diabetes, eye
diseases, skin diseases, and neurocognitive decline.
Major findings
In the process of obtaining digitized X-rays for all partic-
ipants at all time-points of follow-up, we have evaluated
the 3 major methods to score vertebral fractures: quanti-
tative morphometry, semi-quantitative morphometry, and
the qualitative ABQ method [191]. Prevalence of vertebral
fractures differed substantially by the different methods, so
standardization is crucial for patient care and for large
scale epidemiological studies. Using the digitized X-ray
scores, we have for the first time determined population-
based prevalence of Scheuermann’s disease in the Dutch
population to be 4 % [192].
In the relationship of type 2 diabetes with bone health
we observed that diabetic subjects with inadequately con-
trolled glucose control had 1–5 % increased bone mineral
density (BMD) and *50 % increased fracture risk, com-
pared to diabetics with adequately controlled glucose and
to non-diabetics [193].
By studying bone health across different types of hip
osteoarthritis (OA), we observed that subjects with atrophic
OA (i.e., with joint space narrowing but without osteo-
phytes) have *50 % increased fracture risk as compared
to controls without OA [194]. In addition, we found that
hip geometry measures had modest ability to predict hip
OA, in addition to clinical risk factors [195].
Over the last years, we have scored X-ray all radio-
graphs of knee, hip and hand of RS I, II and III for
osteoarthritic features including up to 20 years of follow-
up radiographs. In addition, we have (bilateral) knee MRI
images available for a subset (±1000) individuals of RS
III, including a longitudinal follow-up MRI after 6 years.
In addition, pain sensitivity measurements have been per-
formed including a quantitative assessment of heat sensi-
tivity on the arm using a standardized device (TSA-II
neurosensory analyzer, Medoc), and indications of (wide-
spread) pain in any part of the body using a manikin. This
deep musculoskeletal phenotyping makes the Rotterdam
Study a unique resource to study determinants of
osteoarthritis (OA) and chronic pain and is the largest such
dataset in the world. We have developed and validated
(internally and externally) a prognostic model for knee
osteoarthritis using clinical, genetic and biochemical risk
factors [196]. We demonstrated that CTXII is the most
informative biomarker for prediction of OA, while two
other well-known biomarkers (COMP and C2M) are only
consistently associated with prevalence of OA [197]. This
indicates that COMP and C2M are merely descriptive of
current OA-activity, while CTX2 has additive value for
prediction of the course of disease.
We have identified associations between the presence of
OA and CVD, i.e., measures of atherosclerosis [198].
However, in a longitudinal design, we observed that par-
ticipants with radiographic OA were not at increased risk
of CVD. Our results suggest that the close relation between
disability and osteoarthritis may explain previous reports
suggesting a relationship between OA and CVD [199].
Discordance between having pain and radiologic OA is
a well-established fact. We have identified several factors
associated to pain, which were not related to structural
damage of the joints [200]. We demonstrated that type 3
finger length pattern, an indicator of prenatal androgen
exposure, was associated with having symptomatic knee
OA, and chronic pain [201].
We demonstrated that high-normal thyroid function is
associated with an increased risk of atrial fibrillation [42].
In addition, in the first study to investigate the association
between thyroid function and age-related macular degen-
eration (AMD), we observed an increased risk of AMD
with higher values of thyroid hormone, even in the normal
range of thyroid function [202]. We also for the first time
identified lower TSH levels within the normal range as a
risk factor for developing depression in the elderly [203].
The research line endocrine diseases is also actively
involved in collaborating with economist to study the
biology of economic behaviour, in particular entrepre-
neurial behaviour (and related traits such as educational
attainment). In one of the first collaborative analyses we
found no evidence for a relationship of testosteron levels
with entrepreneurial behaviour [204].
Much of the work of this research is made possible by
large-scale collaboration in consortia, some of which focus
on one particular disease or trait (e.g., GEFOS), while others
are more broad spectrum strategic collaborations (e.g.,
CHARGE, ENGAGE). We are part of several such large
consortia studying genetic and epidemiological risk factors
for osteoporosis (GEFOS, GENOMOS, CHANCES,
CHARGE), osteoarthritis (TREAT-OA, ArcoGen), diabetes
(MAGIC), thyroid disease (CHARGE and Thyroid Studies
Collaboration (TSC)), anthropometric (GIANT) and repro-
ductive traits (CHARGE, REPROGEN, PCOSGEN).
As part of the TSC, we recently published three indi-
vidual-participant data analyses. By analyzing individual
participant data from 13 prospective cohorts (70,298 par-
ticipants) we demonstrated that subclinical hyperthy-
roidism is associated with an increased risk of hip and other
fractures, particularly among those with TSH levels of less
than 0.10 mIU/L and those with endogenous subclinical
hyperthyroidism [205]. An analysis combining data from
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17 cohorts and lead by the Rotterdam Study did not show a
higher risk of stroke with subclinical hypothyroidism
except in participants younger than 50 years of age [206].
A combined analysis in 14 cohorts focusing on risk of
coronary heart disease showed no relationship of TSH
levels within the reference range and risk of CHD events or
CHD mortality [207].
Major GWAS findings
With[82,000 samples collected within the GEFOS con-
sortium a landmark publication was achieved with the
identification of 56 loci influencing bone mineral density in
total explaining*5 % of genetic variation in BMD, and of
which 14 loci also were associated with fracture risk [208].
A large GEFOS meta-analysis is currently underway to
identify risk factors for fracture per se, including all types
of fracture, hip fracture and vertebral fracture.
In a meta-analysis of 15,000 hip OA cases and 54,000
controls assembled in the arcOGen consortium, 5 novel
loci influencing risk of hip OA were identified [209]. In an
analysis of a so-called endo-phenotype of OA, i.e., joint
space width narrowing (JSN) a GWAS among 10,000
subjects we identified a novel locus, called DOT1L, to
influence cartilage thickness, as well as the risk for hip OA
[210]. Interestingly, this gene product is a known drug
target for treating leukemia with several drugs under
development. Our group led a large scale meta-analysis to
chronic wide spread pain in 2700 cases and 14,000 controls
and identified for the first time a genetic locus involved in
pain, i.e., CCT5 [211]. Within the TREAT-OA consortium,
we assessed the effect of genetic variants of 199 OA can-
didate genes and identified a genetic variant in COL11A1
to be associated with hip OA [212]. In addition, we iden-
tified genetic loci affecting either uCTX-II or sCOMP
levels, two biochemical markers for OA [213] and a novel
locus for hand OA [214].
In the largest meta-analysis of GWAS of age-at-menopause
among 62,000 women and which our group led, we identified
13 loci associated with differences in age-at-menopause and
explaining*5 % of the genetic variation [215]. Interestingly,
the majority of the loci most likely involve genes involved in
the DNA repair pathway which points to the importance of
this system in maintaining an error-free stemcell lineage to
which the oocyte belongs. As such the phenotype of age-at-
menopause, represents an interesting model for age-related
changes in cell function maintenance and functions as a model
to identify molecular mechanisms for damage accumulation
and repair during ageing.
In a meta-analysis of GWAS data on TSH levels and
free T4 levels derived from up to 26,000 subjects, 26 loci
were identified explaining 2–5 % of the genetic variation
of TSH and fT4 respectively [216]. There was only limited
overlap between the loci for TSH and fT4, and evidence
was obtained for 5 loci to have sex-specific effects.
A GWAS meta-analysis focusing on TPO autoantibodies
(an important clinical marker for the detection of early
AITD) in 16 cohorts identified five newly associated loci,
three of which were also associated with clinical thyroid
disease. With these markers we identified a large subgroup
in the general population with a substantially increased risk
of TPOAbs [217]. A follow-up study identifying 4 addi-
tional loci associated provided further insight into the
genetic underpinnings of hypothyroidism. A Genetic Risk
Score showed strong and graded associations with markers
of thyroid function and disease in independent population-
based studies [218].
An interesting GWAS involved the analysis of Heli-
cobacter pylori serologic status among members of the
Rotterdam Study and the SHIP cohort [219]. Two novel
loci were identified, TLR1 and FCGR2A, which can help
explain inter-individual differences in risk for H pylori
infection. A larger meta-analysis including several
CHARGE cohorts is currently underway.
For many endocrine biomarkers GWAS have been
performed to identify the genetic loci influencing their
serum levels (e.g., homocysteine, testosteron, SHBG, thy-
roid hormone levels, etc.) and these are also involved in
several mendelian randomization analyses in relation to
major disease endpoints for which these biomarkers have
been suggested to be predictive.
Methods update
For all participants DXA-based bone mineral density
(BMD) measurements of the lumbar spine, dual hip and
total body BMD, as well as determination of body com-
position parameters are assessed with a ProdigyTM total
body fan-beam densitometer (GE Lunar Corp, Madison,
WI, USA). Hip structural analysis (HSA) of DXA scans
including hip strength indexes (using software by GE
Lunar) is determined for all scans. All lumbar spine mea-
surements have been scored for the trabecular bone score
(TBS), Since 2009 we perform iDXA measurements (GE
Lunar) which measures L1–L4 BMD, bilateral total hip and
femoral neck BMD and total body BMD. From the total
body scan, we measure lean mass and fat mass body
composition, including total body, trunk, arm, legs, and
android and gynoid regions of interest. X-ray examinations
of vertebral bodies, hips, knees and hand/wrist are since
2009 obtained by a digitalized Fuji FCR system (FUJI-
FILM Medical Systems) for all participants. Analogue
X-ray photographs from previous time—points at all fol-
low up measurements (*75,000 X-rays) have now all been
digitized. All the X-rays have now been completely
assessed for the presence of vertebral fractures and/or
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degenerative changes of the different joints (e.g.,
osteoarthritis, Scheuermann’s Disease). Vertebral fractures
and deformities are assessed using the classical quantitative
McCloskey–Kanis method, the semi-quantitative Genant
method, and a qualitative algorithm-based technique ter-
med the ABQ method. Incident clinical fractures (of all
bone sites) are obtained from computerized records of the
general practitioners and hospital registries which are
regularly checked by research physicians who review and
code the fracture information. Peripheral Quantitative
Computarized Tomography (pQCT—Stratec XT2000) is a
low-radiation technology (low radiation dose \1 uSV),
which allows measuring structural properties of the bone
and muscle cross section is now applied at the distal and
proximal tibia (weight bearing). Measurements include
geometrical parameters of volume, density of cortical and
trabecular compartments and dimensions of bone and
muscle. The test is done at the proximal tibia.
Muscle strength is assessed in all participants with a
hand grip dynamometer. In addition jumping mechanog-
raphy (Leonardo Novotec medical) has been implemented
for all participants. This platform permits the dynamic
examination of muscle contraction and power. In young
individuals the test is performed asking participants to
execute 2–3 counter movement two-footed stand (jumps)
until both legs are straight and arms moving freely after
receiving the instruction. The test is implemented as the
‘‘stand from a chair test’’ in subjects older than 85 years or
with physical limitations. Muscle mass estimates are
derived from whole body iDXA measurements.
The incidence and progression of OA is assessed using
Kellgren scores obtained from X-rays of hips, knees,
hands, and spine. The complete set of X-rays (all partici-
pants, all follow-up time points) has now been evaluated
for the Kellgren score at these 4 joints. Novel diagnostic
assessments for OA are available using Magnetic Reso-
nance Imaging (MRI) of the knees in a large subset of the
population (n = *1000 RS-III). In addition, pain mea-
surements were added in 2011 in this research line
including a quantitative assessment of heat sensitivity on
the arm using a standardized device, and indications of
(wide-spread) pain in any part of the body using a pain
puppet.
Advanced Glycation End products (AGEs) are glyco-
oxidation products that accumulate in the body over a
lifetime as part of normal ageing but formation is increased
under hyperglycemic and oxidative circumstances. AGE
accumulation in long-lived tissues may be associated with
ageing of multiple organs and with risk to develop multiple
chronic diseases Advanced glycation end-products in the
skin are measured in RS-III-2, RS-I-5 and RS-II-3 by skin
autofluorescence using an AGE-ReaderTM (DiagnOptics
B.V., Groningen, The Netherlands). These data are cur-
rently analyzed in relation to several diseases.
Several specific biomarker assessments in blood/ser-
um/plasma and urine are done for the diagnosis and eval-
uation of risk factors of endocrine and metabolic diseases
(e.g., glucose, TSH, freeT4, steroid hormones, Vitamin D,
calcium, phosphate, CTXII, etc.). Fasting blood samples
are collected along with challenged samples as part of a
glucose tolerance test. Saliva is collected before and after a
dexamethasone-suppression test. Finally, validated ques-
tionnaires evaluating nutrient intake (e.g., calcium and
vitamins) and activities of daily living, allow to evaluate
the role of environmental factors in endocrine conditions
and locomotor diseases of the elderly.
For additional EJE references concerning endocrine and
locomotor diseases see [220–242].
Liver diseases
Objectives
Fibrogenesis of the liver is most probably not only the
result of well known liver diseases, such as viral hepatitis,
alcoholic liver disease or non-alcoholic fatty liver disease
(NAFLD), but rather a complex interaction between a
genetic predisposition and these liver disorders. Liver
research in the Rotterdam Study will concern the associa-
tion between these known causes of liver disease and the
occurrence, magnitude, and progression of fibrosis in
combination with genetic and environmental factors.
Additional research focus is on NAFLD. NAFLD is con-
sidered the hepatic manifestation of the metabolic syn-
drome and has become the most common chronic liver
disease in Western countries in parallel with epidemics of
obesity and type II diabetes mellitus. We aim to study the
occurrence and risk factors of NAFLD in a general popu-
lation and generate insight into the association with car-
diovascular morbidity and mortality.
Methods
Abdominal ultrasound
From February 2009 onwards (cohorts RS-I-5, RS-II-3 and
RS-III-2) onwards, trained technicians perform abdominal
ultrasonography in Rotterdam Study participants. Liver,
biliary tract, gall bladder, spleen, pancreas, and kidneys in
combination with doppler examination of hepatic veins,
hepatic artery and portal vein will be evaluated. All images
are stored digitally and will be reevaluated by an ultra-
sound trained physician.
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Assessment of steatosis
The diagnosis and grading of liver steatosis is based on
ultrasonographic liver brightness, hepatorenal echo con-
trast, deep attenuation and vessel blurring [243].
Non-alcoholic fatty liver disease is diagnosed by pres-
ence of steatosis on ultrasound and exclusion of excessive
alcohol consumption, presence of viral hepatitis, use of
known fatty liver-inducing pharmacological agents, recent
bariatric surgery and a history of inflammatory bowel
disease.
Assessment of fibrosis
Ultrasonographic evaluation of the liver parenchyma and
liver surface is performed in order to assess severe fibrosis
and/or cirrhosis. Additionally, sonographic signs of portal
hypertension will be studied (splenomegaly, venous col-
laterals, portal vein diameter and flow, hepatic venous flow,
and the presence of ascites).
To assess and quantify the grade of fibrosis trained
technicians perform transient elastography in all partici-
pants by the Fibroscan. This test measures non-invasively
and quantitatively the liver stiffness using a probe which
includes an ultrasonic transducer transmitting a vibration
wave through the liver. The velocity of the ultrasonic wave
correlates directly with tissue stiffness [244, 245].
Determinants of interest
The association between factors known to influence liver
function and the occurrence of steatosis and fibrosis are
being studied. Additionally the association of these con-
ditions with age, gender, nutritional intake, concurrent
alcohol intake, risk factors for viral hepatitis, BMI, waist-
to-hip ratio, serum glucose, insulin, and diabetes mellitus,
serum cholesterol and triglycerides are investigated. All
clinical information is obtained by interview (updated with
liver specific questions) and clinical examination. More
recent efforts are focused on identifying common genetic
variants associated with liver steatosis and/or fibrosis.
Main findings
We found a high prevalence of NAFLD of 35.1 % within
the Rotterdam Study population [246]. Main risk factors
for NAFLD were found to be age, decreased physical
activity lever, smoking, increased waist circumference,
glucose intolerance, hypertension, and hyperlipidemia.
Inversely, the risk of NAFLD seems to decrease after statin
therapy [247]. Furthermore, using our ultrasound data as
reference, we examined the performance of the well-known
fatty liver disease index (FLI, based on waist
circumference, BMI, triglyceride and gamma-glutamyl-
transferase (GGT) levels) in the Rotterdam Study popula-
tion, and found that the FLI is a highly valid tool to predict
NAFLD [248]. In another study, we found that all serum
liver enzymes are related to all-cause mortality, as well as
specifically cardiovascular (GGT) and cancer-related (al-
kaline phosphatase and aspartate aminotransferase) mor-
tality [249]. More recently, we have examined the role of
genetic factors in the multifactorial etiology of liver
fibrosis, and found for example that the single nucleotide
polymorphism (SNP) of the interferon gamma receptor 2, a
pro-inflammatory gene known to be associated with pro-
gression to liver fibrosis in chronic hepatitis C patients, also
was related to liver stiffness in the Rotterdam Study par-
ticipants [250]. More studies are currently underway to
look at other known and unknown genetic factors.
Neurological diseases
Objectives
Neuroepidemiologic research in the Rotterdam Study
focuses on the frequency, etiology and early recognition of
the most frequent neurologic diseases in the elderly. We
study neurodegenerative diseases (dementia, including
Alzheimer disease and Parkinson disease), cerebrovascular
disease (both ischemic stroke and intracerebral hemor-
rhage), migraine and polyneuropathy. In all of these dis-
orders clinical symptoms typically become manifest late in
the disease course, the occurrence of clinical disease does
not reflect the underlying spectrum of disease-related
pathology, and most of the clinical syndromes are etio-
logically heterogeneous. Therefore, an additional research
focus is on the causes and consequences of pre-symp-
tomatic brain pathology that can be assessed with non-
invasive modalities, which include MR-imaging, cognitive
testing, gait assessment, and electromyography (EMG).
Major findings
Neurodegenerative and cerebrovascular diseases are highly
frequent in the elderly. The prevalence increases from age
55 to 65 years to age 90 years and above from less than
1 % to over 40 % for dementia [251], from less than 0.5 %
to more than 4 % for Parkinson disease [252], and from
approximately 1 % to nearly 10 % for stroke. The inci-
dence figures follow this pattern of a strong increase with
age over the entire age range, with the age-specific inci-
dence of dementia being identical for men and women at
least until the age of 85 [253] but with men having a higher
age-specific incidence of both stroke and Parkinson disease
than women throughout the age range [254, 255].
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However, more recent numbers from 2000 onwards suggest
that the relative incidence of dementia and stroke may be
lower than in the 1990s [256–258]. Still, in absolute
numbers these disease will dramatically increase in
prevalence over the coming decades.
Vascular pathology and vascular risk factors are associ-
ated with worse cognitive performance [259], which also
translates in people with vascular pathology or risk factors
for vascular disease having an increased risk of dementia,
including Alzheimer disease [260, 261]. Moreover, several
life style factors are associated with the risk of dementia and
Alzheimer disease [262, 263], suggesting that onset of
dementia may at least partly be delayed or prevented.
However, many of these lifestyle factors have only a short-
term effect, suggesting reverse causality to some extent
[264]. Commonly used drugs may also have a role in
development of dementia [265]. Similar risk factor profiles
also underlie cognitive decline prior to the clinical diagnosis
of dementia [266, 267]. We recently investigated the total
contribution that known modifiable risk factors make to total
dementia burden and compared it across decades. We found
that around 30 % of all dementia could be prevented by
effectively treating known risk factors and that this per-
centage had remained stable across the last two decades.
The classical risk factors for stroke also associate with
the risk of stroke in the Rotterdam Study [268–271]. We
have also recently shown emerging risk factors to associate
with stroke [206]. We have also developed prediction rules
for ischemic and hemorrhagic stroke separately [272].
Important to note is that a large amount of stroke goes
clinically undetected [273]. Nearly 20 % of elderly people
have at least one silent brain infarct, and thereby a nearly
fourfold increased risk of clinical stroke, a more than
doubled risk of dementia including Alzheimer disease, and
an increased risk of depression [274].
More recent work in the Rotterdam Study has been
focusing on showing direct links between clinical cere-
brovascular disease and dementia. In this regard, we
showed subclinical heart disease to increase the risk of both
stroke and dementia [275], intracranial carotid calcification
to relate to both diseases [276], and subjective memory
complaints to indicate a strongly increased risk of stroke
[277]. With the advent of genome-wide association studies,
the Rotterdam Study has contributed to large-scale col-
laborations and contributed to the identification of novel
genes underlying the risk of Alzheimer disease and stroke
[278–282].
We have also shown that although currently known
genetic variants for dementia associate with cognition in
non-demented elderly, these do not improve prediction
[283].
Neuroimaging reveals that brain pathology is wide-
spread [284] and can go clinically undetected for a long
time. In addition to the silent infarcts, many apparently
healthy elderly have ischemic changes in their cerebral
white matter, i.e. white matter lesions, that are associated
with an increased risk of dementia, stroke and depression.
Also brain atrophy, especially of the hippocampus, is
already present years before onset of even the earliest sign
of cognitive impairment or subjective complaints. This
emphasizes the need to shift the attention in etiologic
research of neurodegenerative and cerebrovascular disease
to the causes of pre-symptomatic and underlying brain
changes. Technological advances in image acquisition,
optimized imaging sequences and automated post-pro-
cessing of multispectral MR data are major drivers of the
rapid developments in this field. With our current imaging
protocol we can now not only investigate established
markers of brain pathology, such as infarcts, white matter
lesions, and atrophy, but also extend towards novel mark-
ers, such as cerebral microbleeds and diffusion tensor
imaging [285]. We have shown that risk factors profiles for
subclinical disease overlap with those for clinical disease
[280, 286–290]. Also, subclinical white matter lesions and
silent infarcts improve the clinical prediction of incident
stroke [291]. The clinical relevance of subclinical pathol-
ogy is demonstrated by strong associations of these
markers with morbidity and mortality [283, 292–295]. We
have also extensively studied the genetic basis of subclin-
ical brain disease, both in genome-wide settings and in
candidate-gene studies [296–302] (see further section on
population imaging).
Most research on the preclinical phase of neurodegen-
erative diseases, particularly dementia, focuses on either
cognitive performance or brain pathology on neuroimag-
ing. Given that brain pathology is usually diffuse, it is
conceivable that brain functions other than cognition will
also be affected. In this light, we have shown that gait
deteriorates significantly with age [303]. Also, gait and
cognition are linked following a specific pattern of certain
cognitive domains only associated with specific aspects of
gait, but not others [303]. Recently, we have reported our
first findings with migraine and cerebral hemodynamis
[304].
Methods update
Assessment of dementia and Alzheimer disease
In the baseline and follow-up examinations participants
undergo an initial screen for dementia with the Mini
Mental State Examination (MMSE) and the Geriatric
Mental Schedule (GMS), followed by an examination and
informant interview with the Cambridge Examination for
Mental Disorders of the Elderly (CAMDEX) in screen-
positives (MMSE\ 26 or GMS[ 0), and subsequent
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neurological, neuropsychological and neuroimaging
examinations [251, 253]. Of subjects who cannot be
reexamined in person, information is obtained from the
GPs and the regional institute for outpatient mental health
care. A consensus panel makes the final diagnoses in
accordance with standard criteria (DSM-III-R criteria;
NINCDS-ADRDA; NINDS-AIREN).
Assessment of Parkinsonism and Parkinson disease
Participants are screened in the baseline and follow-up
examinations for cardinal signs of parkinsonism (resting
tremor, rigidity, bradykinesia, or impaired postural
reflexes). Persons with at least one sign present are
examined with the Unified Parkinson’s Disease Rating
Scale and a further neurologic exam. PD is diagnosed if
two or more cardinal signs are present in a subject not
taking antiparkinsonian drugs, or if at least one sign has
improved through medication, and when all causes of
secondary parkinsonism (dementia, use of neuroleptics,
cerebrovascular disease, multiple system atrophy, or pro-
gressive supranuclear palsy) can be excluded [252].
Assessment of stroke and stroke subtypes
History of stroke at baseline was assessed through inter-
view and verified in medical records. Putative incident
strokes get identified through the linkage of the study
database with files from general practitioners, the munici-
pality, and nursing home physicians’ files, after which
additional information (including brain imaging) is col-
lected from hospital records. A panel discusses all potential
strokes and subclassifies strokes into ischemic, hemor-
rhagic or unspecified [254, 271]. We also systematically
collect transient ischemic and neurological attacks [305].
Assessment of cognitive function
Global cognitive function is measured through the Mini
Mental State Examination (MMSE) in all surveys. From
the third survey (RS-I-3) onwards we added a 30 min test
battery that was designed to assess executive function and
memory function, and which includes a Stroop test, a
Letter Digit Substitution Task, a Word Fluency Test, and a
15 words Word List Learning test. This test battery was
expanded from the fourth survey onwards (RS-I-4) to
include motor function assessment using the Purdue Peg-
board Test. Moreover, from 2009 onwards we expanded
further by including the Design Orientation Test (DOT)
and a modified version of the International Cooperative
Ataxia Rating Scale (ICARS), which assess visuo-spatial
orientation and ataxia respectively [306–308].
Assessment of gait patterns
Halfway through RS-III-1, we successfully implemented
the assessment of gait in all participants using the GAI-
TRite walkway (http://www.gaitrite.com/). Gait is assessed
using a 5.79 m long walkway (GAITRite Platinum; CIR
systems, Sparta, NJ, USA: 4.88 m active area; 120 H
sampling rate) with pressure sensors. Participants perform
a standardized gait protocol consisting of three different
walking conditions: normal walk, turning and tandem
walk. In the normal walk, participants walk over the
walkway at their own pace. This walk is repeated four
times in both directions (yielding a total of 8 recordings).
In turning, participants walk over the walkway at their own
pace, turn halfway and return to the starting position (1
recording). In the tandem walk, participants walk tandem
(heel-to-toe) over a line visible on the walkway (1
recording). A total of 30 spatiotemporal gait variables are
calculated by the walkway software and downloaded off-
line for further analysis. Subsequently, principal compo-
nents analysis on these thirty gait variables is performed to
derive summarizing factors, referred to as gait domains.
The following gait domains are used: Rhythm, Pace, Pha-
ses, Base of Support, Variability, Tandem, and Turn. Gait
domains can be compared to cognitive domains, in which
each domain reflects a different aspect of the overall con-
cept [303].
Assessment of polyneuropathy
Starting in January 2013, we have successfully imple-
mented a protocol to assess polyneuropathy. This includes
a full work-up including questionnaire, neurological exam,
and EMG in all participants. In coming years, we will
publish on the prevalence, risk factors, and clinical corre-
lates of polyneuropathy in the general population. The
continuous measures of conductivity obtained through
EMG can also serve as excellent endophenotype for
genetic and biomarker studies.
Rotterdam Scan Study: brain imaging within the Rotterdam
Study
In 1991, a random sample of 111 participants underwent
axial T2-weighted magnetic resonance (MR) imaging to
assess presence and severity of white matter lesions [284].
In 1995, a random sample of 563 non-demented partici-
pants underwent brain MR imaging in the context of the
Rotterdam Scan Study. From August 2005 onwards (RS-II-
2 and further), a dedicated 1.5 T scanner is operational in
the research center of the Rotterdam Study, and brain
imaging is performed in all study participants without
contra-indications [285].
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Currently, the follow-up of this latter sample extends to
up to 10 years (see further section on population imaging).
For additional EJE references see [99, 159, 264, 309–
329].
Ophthalmic diseases
Objectives
Ophthalmic research in the Rotterdam Study focusses on
occurrence, causally related determinants, and predictors of
common eye diseases. Our main focus is on age-related
macular degeneration (AMD), glaucoma and myopia, but
we study retinal vessel diameters and (diabetic) retinopathy
as well. In the previous studies, we mostly focused on
common genetic risk variants derived from GWAS and
environmental factors. We will now move on to the study of
rare genetic variants, genetic effects on phenotype, in silico
pathway analysis, biomarkers, and prediction models.
Major findings
Age-related macular degeneration (AMD)
AMD is one of the few complex traits of which a large
proportion of the genetic background has been revealed.
Currently known are 45 loci which show association with
common variants, and a handful of genes which harbor rare
genetic variants. Four genes have very common SNPs with
major effects, and carriers of more than one of these
variants have a more than 50 % chance of developing
AMD. Many of the identified genes play a role in the lipid
pathway. Together with the 3 continent AMD consortium
[330], we studied lipid genes in conjunction with serum
lipid levels and incidence and progression of AMD in a
total of 6950 participants. After adjustment for all con-
founders, we found no significant relationship between
lipid levels, lipid genes, or statin-use in this meta-analysis.
This points out that potential relationships between car-
diovascular determinants and AMD may be indirect.
As hormones have been hypothesized to play a role in
AMD, we studied thyroid-stimulating hormone (TSH) and
free thyroxine (FT4) [202]. 5573 participants from the
Rotterdam Study were followed for an average period of
6.9 years during which 805 persons developed AMD.
Higher FT4 levels were associated with a higher risk of
AMD, and participants in the highest quintile had a 1.3 fold
increased risk of developing AMD. This relation was also
found in euthyroid participants, indicating that this rela-
tionship exists already at a subclinical level.
Our gene-environment analyses focused on nutrition. We
pooled the dietary data that we collected at baseline with
data from the Australian population-based Blue Mountain
Eye Study, and evaluated development of AMD in 4632
persons during 15 years of follow up [331]. For those at high
genetic risk (based on carriership of the CFH and ARMS2
genes), we found a strongest risk reduction when their intake
of lutein/zeaxanthin (risk reduction 20 %) and fish (risk
reduction 40 %) was high. These data are highly clinically
relevant, as they provide leads for doctors on how to advise
patients at high genetic risk to alter their fate.
Direct-to-consumer companies have exploited the recent
genetic advances to market genetic testing for AMD. We
aimed to evaluate the merit of these companies by sending
DNA samples of our own researchers to these labs, as well
as to our own Rotterdam Study laboratory using our own
developed prediction model [332]. The results from the
companies showed a 1.6-fold difference for overall relative
risk to an up to 12-fold difference for lifetime risk. Most
important reasons for the differences in risks were the
testing of only a limited set of genetic markers, the choice
of the reference population, and the methodology applied
for risk calculation. We believe there is ample room for
improvement here.
Myopia (nearsightedness)
A myopia boom is taking place all over the world. We and
others found an increasing prevalence of myopia as well as
a rise of the more extreme end of the spectrum, high
myopia (refractive error of -6 diopters and beyond). In
collaboration with studies in the European Eye Epidemi-
ology consortium (E3), we performed a meta-analysis of
refractive error prevalence [333]. We used the 2010
European Standard Population and studies ages between 25
and 90 years. The prevalence standardized to age 50 in
Europe were 30.6 % myopia, 2.7 % high myopia, 25.2 %
hyperopia and 23.9 % astigmatism. However, the preva-
lence of myopia was up to 47 % in those aged 25–29 years,
showing a generation increase. In the search for explana-
tions for this strong rise, we explored the association with
education [334]. We found that higher education is strongly
associated with myopia, but it seems to be an additive
effect and does not explain the entire frequency rise.
The clinical relevance of myopia is determined by its
visual consequences. We evaluated the risk of severe visual
impairment for the entire range of refractive errors, and
found that high hyperopia as well as high myopia carried
an increased risk of visual impairment [335]. High myopia
had the most severe visual consequences. One in three high
myopes developed severe visual impairment during his/her
lifetime, and risks went up to[90 % for those with axial
lengths of 30 mm and higher. The most common cause of
visual impairment was irreversible myopic macular
degeneration.
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In recent years, we acquired more knowledge on the
genetic background of myopia. With our international
CREAM consortium (Consortium of Refractive Error And
Myopia), we further explored common genetic associations
with axial length (AL). We replicated the association with
the ZC3H11B gene [336], and found eight other genome-
wide significant loci in a meta-analysis. These loci were in
linkage disequilibrium with the genes RSPO1, C3orf26,
MIP, ZNRF3, LAMA2, GJD2, CD55, ALPPL2 and
ZC3H11B. The last five were also associated with refrac-
tion, indicating significant overlap between AL and
refractive error. In addition to AL, we focused on the
extreme ends of spherical refraction, and found 11 loci to
be associated with both myopia and hyperopia [337]. The
effects of the risk alleles in these loci were in opposite
directions, providing support for the existence of only one
refractive error trait. We also focused on astigmatism, a
refractive error which results from radial inconsistencies of
the cornea as well as the lens [338]. Astigmatism is a
common companion of myopia and hyperopia, and is
thought to have a genetic basis as well. We conducted a
meta-analysis on refractive astigmatism in CREAM, and
found a significant hit with a marker downstream of the
neurexin-1 (NRXN-1) gene (P = 3.92E-8). No other
genome wide significant loci were found. This suggests a
more complex genetic background for astigmatism than for
spherical aberrations. We will continue to pursue the search
for astigmatism genes the coming years.
Future research on myopia will be focused on finding
the missing genes with exome analyses, whole genome
analyses, and family studies; on pathway analysis and
functional studies; and on development of prediction
models.
Primary open-angle glaucoma (POAG)
Although many genetic risk factors for primary open-angle
glaucoma (POAG) and POAG related endophenotypes
have been identified these last years, a large part of the
heritability is still unexplained. To this end, we combined
our efforts with international study groups in the Interna-
tional Glaucoma Genetics Consortium (IGGC). This con-
sortium investigated GWAS data on POAG and POAG-
related endophenotypes including intraocular pressure
(IOP), vertical cup-disc ratio (VCDR), cup area (CA) and
disc area (DA).
Intraocular pressure
A meta-analysis focused on GWAS of IOP was performed
including 35,296 subjects from 7 countries participating in
IGGC [339]. Four new IOP-associated loci were identified
(FNDC3B, ABCA1, ABO, and a region on chromosome
11p11.2). Three genes also showed significant association
with POAG. In a GWAS study of IOP in the Rotterdam
Study I and Rotterdam Study II using 1000 Genomes
imputations, we identified a new locus (ARHGEF12) for
IOP [340]. We replicated this finding in 5 other population-
based studies, and found a significant association with
POAG in two independent case–control studies. The
ARHGEF12 gene is involved in IOP regulation via the
RhoA/RhoA kinase, and novel drugs targeting this pathway
show promising results.
Vertical cup–disc ratio
A meta-analysis of VCDR was performed in 27,878 indi-
viduals [341]. Ten novel loci associated with elongation of
the cup were identified (COL8A1, DUSP1, EXOC2,
PLCE1, ADAMTS8, RPAP3, SALL1, BMP2, HSF2 and
CARD10). Persons in the highest quintile of genetic risk
had a 2.5-fold increased risk of POAG compared with
those in the lowest quintile. Pathway analysis implicated a
negative regulation of cell growth and cellular response to
environmental stress as key pathological pathways.
Optic disc area parameters
A meta-analysis investigating CA and DA in 24,089 indi-
viduals identified 10 novel loci for CA (DHRS3, TRIB2,
EFEMP1, FLNB, FAM101, DDHD1, ASB7, KPNB1,
BCAS3, and TRIOBP) and 10 novel loci for DA
(CDC42BPA, F5, DIRC3, RARB, ABI3BP, DCAF4L2,
ELP4, TMTC2, NR2F2, and HORMAD2) [342]. These
loci explained an additional part of the variance in glau-
coma. These results showed that CA and DA—measure-
ments were of additional value in the identification of
causal factors for glaucoma.
Functional genetics of POAG
Our previous glaucoma studies had showed that the SIX1/
SIX6 locus was associated with VCDR and POAG. Fine
mapping and exome sequencing of this region revealed 2
new variants in the SIX6 gene and pointed to SIX6 as the
responsible gene for the associated signal. We further
aimed to investigate the functional consequences of this
gene by studying the effect of a transient knockdown of
SIX6 using morpholinos [343]. We found that absent
function of SIX6 led to a 30–50 % decrease in eye
dimensions. Histologic examination revealed an underde-
veloped lens and a thin optic nerve. Expression analysis
revealed up-regulation of CDKN2B, a cyclin-dependent
kinase inhibitor that is involved in cell cycle regulation and
TGFß-induced growth inhibition that has been consistently
implicated in POAG. These results confirm that SIX6 plays
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a role in eye growth and development, and that regulation
of the CDKN2B protein appears to be a downstream
mechanism. Future steps for POAG genetics will focus on
1000 Genomes imputations, and analysis of exome chip
and exome sequencing data.
POAG diagnostics and imaging
All over the world, retinal imaging is becoming more and
more a diagnostic tool for POAG. Imaging with optical
coherence tomography (OCT) has made it feasible to
visualize and measure the retinal ganglion cell and nerve
fiber layer, two structures which are key elements in
glaucoma. We collaborated with the Iowa Imaging group
led by Michael Abramoff to measure the various layers of
the retina using automated digital algorithms. Together
with the Iowa group, we determined the screening perfor-
mance of OCT layer thickness measurements in the peri-
papillary and macular region for POAG in the Rotterdam
Study [344]. Mean thickness of the retinal ganglion cell
layer in the inferior half of the macular region showed the
highest predictive value (AUC 0.85; 95 % CI 0.77–0.92)
and sensitivity (53.7 %; 95 % CI 38.7–68.0 %) for glau-
coma. The mean thickness of the peripapillary retinal nerve
fiber layer had AUC 0.77 (95 % CI 0.69–0.85) and sensi-
tivity 24.4 % (95 % CI 13.7–39.5 %). These data shed new
light on the occurrence of glaucomatous events at the
cellular level, and may indicate that the macula is more
important as an initiation site than the optic disc.
Methods update
At baseline and follow-up examinations participants
undergo ophthalmic measurements including best-cor-
rected ETDRS visual acuity, refractive error, Goldmann
applanation tonometry, keratometry, slit lamp examination
of the anterior segment and visual field testing. In phar-
macological mydriasis we make 35 color photographs of
the macular area, and 20 simultaneous stereoscopic imag-
ing of the optic disc and macular area. Since the fourth
follow-up, 35 stereoscopic color photographs of the optical
disc and the macular area were made (RS-I-5). Analog
fundus photography was replaced by stereoscopic digital
imaging of the macular area and optic disc since the third
follow-up examination. Optic nerve head analysis with a
Heidelberg Retina Tomograph, macular pigment density,
and melanin optical density measurements were added
during the third follow-up (RS-I-3). At fourth follow-up
examination, fourier domain optical coherence tomography
of the macular area and optical disc, axial length and width
measurements of cornea, anterior chamber, lens, posterior
chamber and retina measured with Lenstar; and fundus
autofluorescence, infra-red and red-free measurements
were added (RS-I-5).
The classification of AMD, POAG, refractive error, and
retinal vessel diameters remained unchanged.
For additional EJE references see [345–349].
Psychiatric diseases
Objectives
The aim of the psychiatric research in the Rotterdam Study
is to investigate the determinants, correlates and conse-
quences of common psychiatric problems in the elderly.
The focus lies on studies of depressive and anxiety disor-
ders, sleep disturbances, addiction to smoking, and com-
plicated grief.
Study design update
Initially, the psychiatric data collection was very limited
but this was expanded strongly in the last 15 years. In the
second visit most participants were screened for depressive
symptoms and from the third examination onwards (RS-I-
3), in 1997–1999, depressive disorders have been ascer-
tained systematically. Assessments of anxiety disorders,
sleeping disturbances, and complicated grief were added in
the subsequent examination (RS-I-4) and have been per-
formed in all follow-up visits of the original and added
cohorts. Recent additions to the protocol included a
screening for psychotic symptoms and, from January
2012–October 2014, ambulatory polysomnography.
Major determinants
Psychiatric research in the Rotterdam Study focuses on
biological risk factors. The vascular depression hypothesis
was tested with different measures of atherosclerosis,
arterial stiffness and cerebral blood flow [350]. We
examined whether blood levels of vitamins and fatty acids,
immune parameters, and markers of folate metabolism
increased the likelihood of depression. Diurnal patterns of
cortisol secretion were related to psychiatric and other
outcomes such as subclinical atherosclerosis. Within the
psychiatric research line, very few candidate gene studies
were performed, whereas several GWAs were conducted in
collaborative efforts focusing on depressive symptoms,
sleep, anxiety and cortisol [351–354]. Several, mostly
cross-sectional studies of brain morphology as possible
determinants and correlates of common psychiatric disor-
ders were completed [292]. Current data collection
includes a dexamethasone suppression test to measure
hypothalamic–pituitary–adrenal axis activity in all
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participants, which is unique in a population-based study.
Also, psychiatric problems and psychological traits such as
happiness, sleep duration, and depression are increasingly
studied as determinants of health and mortality [355].
Methods update
Assessment of depressive disorders and symptoms
Information on depression is obtained from (a) psychiatric
examinations, (b) self-reported histories of depression,
(c) medical records, and (d) registration of antidepressant
use [356]. The psychiatric examination during each visit
consists of a assessment and screening with the Center for
Epidemiologic Studies Depression Scale (CES-D).All
screen-positive participants identified by a CESD score of
16 or above in each follow-up examination, are interviewed
by a clinician (psychiatrist, psycho-geriatrician or clinical
psychologist) with the semi-structured clinical interview
(Dutch version of the Schedules for Clinical Assessment in
Neuropsychiatry-SCAN) to diagnose depressive disorders.
Major depressive disorders are classified according to the
Statistical Manual of Mental Disorders, 4th revised edition
(DSM-IV) criteria. To continuously monitor incidence of
depression throughout follow-up, information on the
occurrence of episodes of depression and depressive
symptoms are continuously collected from general practi-
tioners medical records. All medical records such as hos-
pital discharge letters, specialists reports, and notes of the
GP are extracted and copied by a research-assistants
looking for potential depressive symptoms. These extracted
data are rated and categorized by two medical doctors.
Consensus decisions are made for disagreeing categoriza-
tions. Finally, incident episodes of MDD were defined as
the first event that chronologically occurred in one of the
two data sources described above.
Assessment of anxiety disorders
Anxiety disorders are diagnosed as part of the home
interview. Trained lay interviewers conduct a slightly
adapted version of the Munich version of the Composite
International Diagnostic Interview (M-CIDI) to assess the
following anxiety disorders with a computerized diagnostic
algorithm according to DSM-IV criteria: generalized anx-
iety disorder (GAD), panic disorder, agoraphobia, social
phobia and specific phobia [357]. The M-CIDI was
specifically designed to obtain DSM-IV diagnoses and
test–retest reliability for anxiety disorders is good (kappa
for any anxiety disorder: 0.81). For all anxiety disorders,
except GAD, one-year prevalence is assessed. In addition,
the HADS-A is used to assess anxiety traits continuously.
Assessment of sleep and circadian rhythms
Sleep quality and disturbance is measured with the
Pittsburgh Sleep Quality Index. In addition, sleep duration
and fragmentation are assessed with actigraphy, a method
that infers wakefulness and sleep from the presence or
absence of limb movement [358]. In total, nearly 2000
persons participated in this actigraphy study: they wore an
actigraph and kept a sleep diary for, on average, six
consecutive nights. Follow-up assessments of actigraphic
assessments in these participants are currently scored.
Ambulatory polysomnographic (PSG, i.e., full sleep EEG)
recordings of one night have been conducted in 940
participants. We scheduled home visits of a research
assistant who placed the sensors to record an ambulant
PSG (Vitaport 4; Temec, Kerkrade, the Netherlands). The
PSG included six EEG channels, F3/A2, F4/A1, C3/A2,
C4/A1, O1/A2, O2/A1, bilateral electrooculography,
electromyography, electrocardiography, respiratory belts
on the chest and abdomen, oximetry, and a nasal pressure
transducer and oronasal thermocouple to measure airflow
[359]. All recordings were scored according to American
Association of Sleep Medicine guidelines by a registered
Sleep Technologist. Recordings were manually scored in
30-s epochs for identification of sleep stages; each epoch
was scored as Wake, N1, N2, N3 or REM sleep. For each
sleep stage, the duration and latency was determined. In
addition, we used PRANA (PhiTools, Strasbourg, France)
software to automatically measure the microstructure of
sleep, e.g. spindles and REM density. Polysomnography
recordings are also used to calculate the apnea hypopnea
index.
Circadian rhythms: Sleep-wake activity patterns over a
week are studied with actigraphy as a marker of circadian
rhythms. In more than 1700 persons we calculated inter-
daily stability, i.e. the stability of the rhythm over days and
the intra-daily variability, i.e. the fragmentation of the
rhythm [360].
Assessment of grief
All participants are asked if they are currently grieving. If
the answer is positive we ask formal follow-up questions
‘‘When did this person die?’’, and ‘‘Who was this person?’’
The participants who answered the first question affirma-
tively are assessed for complicated grief with the Dutch
version of the Inventory of Complicated Grief (ICG). The
ICG is considered the gold standard for measurement of
complicated grief in older adults because it has high
internal consistency, good convergent and criterion
validity.
678 A. Hofman et al.
123
Major findings
Depression: The incidence and recurrence of depression in
the elderly was estimated by continuously monitoring
depression during a follow-up period of, on average,
8 years [356]. In total, 566 depressive syndromes and 1073
episodes of clinically relevant depressive symptoms
occurred. For depressive syndromes, the incidence rate was
7.0 (95 % CI 6.0–8.3) per 1000 person-years and the
recurrence rate was 27.5 (95 % CI 23.7–32.1) per 1000
person-years. The recurrence rate of depressive syndromes
was equal for women and men.
In a series of studies we found some evidence for the
vascular depression hypothesis. More severe coronary and
extra-coronary atherosclerosis were associated with a
higher prevalence of depression, as were cerebral haemo-
dynamic changes [350]. However, our data did not support
a specific symptom profile of vascular depression as pre-
viously defined. Most importantly, we found no longitu-
dinal relation between peripheral atherosclerosis and
incident depression [361]. Recently, we prospectively
studied cerebral vascular risk factors such as white matter
lesions, silent infarcts or blood flow in relation to depres-
sion [362]. We found evidence that small vessel disease
predicted the onset of depression. This suggests that
atherosclerotic processes in the brain are a specific risk
factor for depression.
Sleep: We investigated the relationships of sleep dura-
tion with both cardiovascular risk factors and psychiatric
disorders. We also aimed to explain sex differences in
subjective and actigraphic sleep parameters [363]. If
assessed by diary or interview, elderly women consistently
reported shorter and poorer sleep than elderly men. In
contrast, actigraphic sleep measures showed shorter and
poorer sleep in men. These discrepancies were partly
explained by sleep medication use and alcohol consump-
tion. The first results using polysomnography to measure
sleep EEG suggest that REM-density is a marker of
depressive symptoms in the general population [359].
Other results suggest that sleep apnea and depressive
symptoms are not related, although both result in fatigue
[364].
Anxiety: We found that prevalent anxiety disorders
fulfilling DSM-IV criteria may be much less co-morbid
with depressive disorders than previously thought if the
disorders are assessed with different diagnostic instru-
ments. On the other hand, a history of depression is very
common in persons with prevalent anxiety disorder [365].
Complicated grief: In our population-based study of
5741 elderly persons, current grief was reported by 1089
participants, of these 277 (25 or 4.8 % of total) were
diagnosed with complicated grief, the vast majority of
which had no clinical symptoms of anxiety or depression.
Persons with complicated grief were older, had a lower
level of education, and more often had lost a child [366].
Recently published work suggests that complicated grief
occurs together with structural brain atrophy more often
than expected by chance [367].
Genetics of common psychiatric disorders: In the past
years, we have performed a series of genome-wide asso-
ciation studies of the above psychiatric and psychological
phenotypes, mostly as part of the CHARGE consortium.
Initial analyses have yielded no convincing genome wide
significant results as studies were strongly underpowered,
psychiatric phenotypes do not present very homogenous
entities and are highly polygenetic. Disappointingly, the
genome wide analyses of intermediate phenotype in the
field of psychiatry such as cortisol or executive function
have hardly been more successful [368, 369]. However,
more recent work with larger sample sizes as part of the
PGC consortium shows promising results.
Finally, ongoing psychiatric research projects examine
whether and how psychological well-being or psychiatric
problems contribute to survival. Most importantly, we are
interested in whether the effects are specific to certain
behaviour or emotions, are independent of confounding by
physical disease, or can be explained by lifestyle,
immunological or hormonal regulation [370].
For additional EJE references see [153, 371–384].
Respiratory diseases
Within the Rotterdam Study, the prevalence, incidence and
natural history of common respiratory diseases in older
subjects are investigated. The main focus of the respiratory
epidemiology group is chronic obstructive pulmonary dis-
ease (COPD), but the research group also investigates acute
respiratory tract infections, pneumonia, asthma, asthma and
COPD overlap syndrome (ACOS) and lung cancer. In
addition, the respiratory epidemiology group aims to elu-
cidate the clinical and genetic determinants of lung func-
tion, encompassing spirometry and diffusing capacity of
the lungs. Several complementary epidemiologic approa-
ches are performed within the Rotterdam Study: clinical
epidemiology, genetic epidemiology, molecular epidemi-
ology and pharmaco-epidemiology. Thanks to an excellent
collaboration with the investigators of the Generation R
birth cohort study, also life course epidemiologic studies
are performed to elucidate the early life origin of complex
respiratory traits and diseases in adulthood [385].
Lung function
At each cross-sectional round of paraclinical investigations
at the Ommoord research center, spirometry is performed
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using a Master Screen PFT Pro by trained paramedical
personnel according to the American Thoracic Society
(ATS)/European Respiratory Society (ERS) guidelines
[386.] In the most recent round of paraclinical investiga-
tions (from March 2009 till June 2014), diffusing capacity
of the lungs (DLCO) has been measured in all participants
of the three cohorts (RS I-5, RS II-3 and RS III-2) using the
Master Screen PFT Pro according to the ATS/ERS
guideline on standardisation of the single-breath determi-
nation of carbon monoxide uptake in the lung [387]. The
aim of the measurements of spirometry and diffusing
capacity of the lungs is fourfold: first, to diagnose COPD
according to the Global initiative for Obstructive Lung
diseases (GOLD) guidelines; second, to determine the
severity of disease as evidenced by the severity of airflow
limitation in those subjects with an obstructive spirometry
(defined as a ratio of Forced Expiratory Volume in one
second (FEV1) to Forced Vital Capacity (FVC)\70 %);
third, to phenotype COPD subjects accurately by taking
into account emphysema as evidenced by a decreased
DLCO; and finally, to investigate the decline of lung
function over time as a marker of disease activity and
progression in COPD.
In collaboration with the CHARGE consortium, we have
performed landmark Genome Wide Association Studies
(GWAS) of lung function, which clearly implicate early
life origins of adult lung function. The first GWAS of the
FEV1/FVC ratio, a spirometric measure of airflow limita-
tion (mainly due to airway obstruction), revealed eight
genetic loci [388]. Interestingly, using the hypothesis-free
GWAS approach, two genetic loci—near the hedgehog
interacting protein (HHIP) gene on chromosome 4 and in
the gene patched 1, the receptor for hedgehog, on chro-
mosome 9—were significantly associated with airflow
limitation, and appeared to be involved in the same bio-
logical pathway, namely the hedgehog pathway. This
hedgehog pathway regulates the delicate intercellular
communication between lung epithelial cells (derived from
the endoderm) and lung mesenchymal cells such as smooth
muscle cells (derived from the mesoderm) in foetal life,
and is crucial for the branching morphogenesis of the
lungs. In the second GWAS of FEV1/FVC in more than
90,000 subjects, thanks to a collaboration between the
CHARGE and Spirometa consortia, 16 additional genetic
loci have been discovered, including genes involved in
oxidative stress responses (GSTD), homeostasis of extra-
cellular matrix proteins (ADAM19, MMP15), Transform-
ing Growth Factor-b (TGFB) signalling (TGFB2) and
branching morphogenesis (RARB) [389]. Together, these
two GWAS implicate that early life events during embry-
onic life and infancy might contribute to lung function in
adulthood. Recently, we—in collaboration with the
CHARGE consortium—have published a GWAS of Force
Vital Capacity (FVC), a marker of lung volume and an
independent predictor of survival in adult populations
(hence the word ‘‘vita’’ or ‘‘life’’ in the term FVC) [390].
Chronic obstructive pulmonary disease
The prospective population-based Rotterdam Study is ide-
ally suited to investigate key research questions of Chronic
Obstructive Pulmonary Disease (COPD) regarding its
pathogenesis, epidemiology, environmental and genetic risk
factors, natural history of the disease, phenotypes, exacer-
bations and co-morbidities [391]. Based upon results of
spirometry, medical files of general practitioners and letters
of respiratory physicians, we have currently a validated
diagnosis of COPD in approximately 2000 participants (out
of the total cohort of 15,000 subjects), with a median follow-
up of 12 years, implicating more than 24,000 person-years
of follow-up [392]. Importantly, the COPD participants are
well phenotyped, thanks to a combination of crucial infor-
mations: (1) questionnaire-based data (e.g. respiratory
symptoms including shortness of breath, cough and sputum),
(2) smoking history, (3) medical information on chronic
diseases and acute events (based upon medical files from
general practitioners and hospital letters), (4) lung function
tests (spirometry and diffusing capacity of the lung), (5)
exacerbation history (of both moderate exacerbations and
severe exacerbations requiring hospitalisation), (6) drug
dispensing data (of oral and inhaled treatments) and (7)
mortality data in nearly all COPD subjects. In addition, in a
large random sample of Rotterdam Study participants
(n = 2500), CT scans of the chest have been performed for
imaging of the heart, coronary arteries and mediastinal large
vessels, but also providing imaging of the lungs at inspira-
tion and the opportunity to quantify the degree and extent of
emphysema.
COPD does not only affect the airways and lungs, but is
also associated with extra-pulmonary manifestations and
co-morbidities. In the Rotterdam Study, we have demon-
strated that COPD is associated with cerebrovascular
macro- and micro-angiopathy [393, 394]. In a cross-sec-
tional analysis, COPD cases had a twofold increased
prevalence of carotid artery wall thickening on ultra-
sonography compared with controls with normal lung
function [393]. Importantly, the risk of carotid wall thick-
ening increased significantly with severity of airflow lim-
itation. Moreover, on magnetic resonance imaging (MRI)
of the extracranial carotid arteries, lipid core plaques were
more frequent in COPD subjects than in control subjects.
Since lipid core plaques are more vulnerable to rupture,
this might predispose COPD patients to the occurrence of
stroke (especially ischemic stroke). In a second study on
cerebrovascular co-morbidities in COPD, we demonstrated
that subjects with COPD had a higher prevalence of
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cerebral microbleeds on MRI of the brain, which is a novel
marker of cerebral small vessel disease [394]. The asso-
ciation was independent of age, sex, smoking status,
atherosclerotic macroangiopathy, serum creatinin, total
cholesterol and triglycerides. Intriguingly, regarding the
specific location of the cerebral microbleeds, COPD sub-
jects had a significantly increased prevalence of microb-
leeds in deep or infratentorial locations. These findings
were confirmed in longitudinal analyses restricted to sub-
jects without cerebral microbleeds at baseline, since COPD
was an independent predictor of incident cerebral microb-
leeds in deep or intratentorial locations [394]. To what
extent these imaging abnormalities contribute to the
observed gait disturbances in patients with COPD [395],
needs to be elucidated.
Several studies have shown that COPD is associated
with cardiovascular diseases, encompassing ischemic
heart disease, acute myocardial infarction, cardiac dys-
rhythmia (e.g. atrial fibrillation) and heart failure.
Recently we have demonstrated that subjects with COPD
have an increased risk of sudden cardiac death [396]. The
risk increased particularly 5 years after diagnosis of
COPD and in patients with frequent exacerbations of
COPD. Since in observational studies in patients with
COPD beta-blockers have been shown to reduce mortal-
ity, and since we have demonstrated that the effects of
cardio-selective beta-blockers on pulmonary function are
minimal in the general population and in COPD subjects
[397], it is time to perform interventional studies with
beta-blockers in patients with COPD in order to reduce
the high cardiovascular and all-cause mortality in this
vulnerable patient population.
Since COPD is characterized by chronic pulmonary
inflammation and an accelerated ageing of the lung, we
have investigated whether COPD is associated with frailty.
Using the Fried criteria of (physical) frailty, evaluating
nutritional status (unintentional weight loss), grip strength,
mobility (slow walking speed), physical activity and
exhaustion, we have determined the prevalence of frailty in
2.833 participants of the Rotterdam Study (median age:
74 years): 5.8 % were frail [229]. Frail elderly had lower
quality of life, had more frequently fallen or been hospi-
talized, and were at increased risk of dying within three
years compared to non-frail elderly [229]. The prevalence
of frailty in subjects with COPD (10.2 %) was significantly
higher than in subjects without COPD (3.4 %). After
adjusting for age, sex, smoking, corticosteroids and other
confounders, COPD subjects had a more than twofold
increased prevalence of frailty [395]. Importantly, COPD
elderly who were frail had a significantly worse survival.
Additional EJE references [398–403].
Genomics and biomarker studies
Objectives
The team in this research line focusses on bio-banking
activities of the participants of the Rotterdam Study and
investigates biological determinants of disease (i.e., DNA,
RNA, proteins, metabolites, microbes, etc.). Bio-banking
involves collecting, storing and managing the biological
tissues of participants of the Rotterdam Study at all follow-
up measurements. This concerns mainly blood, urine, sal-
iva, hair and faeces. We have further started to store full
blood samples for the isolation of induced pluripotent stem
cells. The research focus of this group concerns assessment
of biological determinants of disease (biomarkers) in these
biomaterials and the analysis of markers using genomic
technologies (such as SNP arrays and next generation
sequencing (NGS)).
Major findings
Rotterdam Study investigators are playing leading roles in
several of the large global consortia focused on assessing
the contribution of complex disease gene variants by
prospective meta-analysis across many epidemiological
cohorts, such as in CHARGE and ENGAGE, and in many
disease/phenotype focused efforts such as ADSP, IGAP,
PERADES, GIANT, GEFOS, REPROGEN, TREATOA,
DIAGRAM, etc. Since 2005 the genome wide association
study (GWAS) has changed the field of complex genetics,
and identified a still growing list of common variants
contributing to disease risk and explaining genetic variance
of traits. While this large scale global collaboration has
originated from the GWAS era, we now see similar con-
sortia being built around the newer genomics datasets with
RNA expression profiles, DNA methylation profiles, and
the NGS datasets on DNA, RNA and microbiomes,
including the BBMRI-NL sponsored BIOS consortium.
The Rotterdam Study has GWAS data for almost the
complete dataset summing to over 12,000 DNA samples,
and is involved as a major collaborative centre for meta-
analysis studies of GWAS data, including national pro-
grams (RIDE, NGI-NCHA), EU-funded projects (GEFOS,
TREATOA, ENGAGE), and voluntary collaborations
(GIANT, MAGIC, CHARGE). Especially, from the
CHARGE consortium (the Rotterdam Study together with
the Framingham Study, AGES, CHS, and ARIC) many
important publications have emerged on a wide variety of
phenotypes and diseases from all major research lines in
the Rotterdam Study [69]. You can find them discussed
under the subheadings of each individual research line.
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Data collection, storage and management
At each examination at the research centre, blood, serum,
plasma (citrate, heparine), and saliva is collected, as well as
EDTA tubes for DNA and PAXgene tubes for RNA iso-
lation. Fasting blood samples are collected along with
challenged samples as part of a glucose tolerance test.
Saliva is collected before and after a dexamethasone-sup-
pression test. Saliva is frozen at -196 C before and after
the challenge and stored at -80 C. To obtain serum and
plasma, tubes are centrifuged according to a protocol
standardising time and conditions from the drawing of
blood to centrifugation. All samples including the full
blood are snap frozen at -196 C using liquid nitrogen and
stored at -80 C. Overnight urine samples are collected at
home, frozen at -196 C at the research centre and stored
at -80 C.
DNA is isolated from whole blood at one laboratory at
Erasmus MC by a manual salting-out protocol and is
subsequently stored in Eppendorf tubes at -20 C. A copy
of the complete DNA collection of *13,000 samples has
been transferred to Matrix 2D-barcode tubes in 96-well
format at another location. This copy has been subjected to
normalization of DNA concentrations and made suitable
for handling in 96- and 384-well micro-titer plates for
subsequent downstream genomic analysis.
Starting with the RS-III round of data collection, blood
drawing has also been taken place with PAXgene tubes,
from which whole RNA is isolated and stored at -80 C.
This is now ongoing for the whole study population fol-
lowing the cycles of visits to the research centre.
Similarly, with the RS-III round, collection of faeces
material has been initiated for the intestinal microbiome
analysis. A collection pot is distributed at the research
centre visit which is to be used at home and then by postal
mailed returned to Erasmus MC where DNA is isolated and
stored at -80 C. This is now ongoing for the whole study
population following the cycles of visits to the research
centre.
For data management, an in-house customized sample-
management system has been developed. All genomic data
of the Rotterdam Study (e.g., SNP array, RNA expression,
NGS DNA and RNA, microbiome 16S NGS) are generated
in one laboratory which keeps all raw data, while QC-ed
and extracted data are stored and managed in the central
data repository of the Rotterdam Study.
Blood serum/plasma assessments
For all participants, serum cholesterol, HDL, LDL,
triglycerides, glucose and glucose levels are assessed. In
urine, micro albumin and creatinine are determined in all
participants. Recently, a new ‘‘baseline’’ serum biomarker
dataset has been generated at the Erasmus MC Clinical
Chemistry Laboratory and the Endocrine Laboratory con-
sisting of RS-I-3, RS-II-2, and RS-III-1 samples
(N = *10,000). These measurements include a steroid
profile by mass-spectrometry (e.g., estrogens, androgens,
cortisol), vitamin D, thyroid hormones (TSH, free T4),
interleukins, CRP, IGF1, insulin, iron-parameters (iron,
ferritin and transferrin saturation), fibrinogen, homocys-
teine, folic acid, riboflavine, pyridoxine, SAM/SAH ratio,
cobalamine, Lp-PLA2, Fas/Fas-L, and abeta42/40.
Human genomics facilities
The Rotterdam Study uses one Erasmus MC laboratory (the
Human Genotyping Facility, HuGE-F, at the department of
Internal Medicine) for all its genomic studies on DNA,
RNA, methylation, microbiome, etc. The facility use high-
end automated machinery including 2 Caliper pipetting
robots (including a TwisterII, and integrated plate reader
(OD 260/280), 2 Tecan EVO 150 Freedom pipetting robots,
a Deerac Equator NS808 nanoliter liquid dispenser, PCR
machines, an ABI7900HT Taqman machine (running 1 ng
gDNA in 2 microliter reactions), 2 Illumina iScan micro-
array readers, one Roche 450 GS Junior sequencer, two
Illumina HiSeq2000 sequencing machines, and has access to
Illumian HiSeq2500 and Myseq machines. DNA sample
handling is centred on 384-well plates. Single SNP geno-
typing studies are done mostly using Taqman and Sequenom
genotyping with throughputs at 30,000 genotypes per day.
We work with reduced amounts of input genomic DNA of 1
nanogram per genotype. This facility has been generating all
GWAS data for the Rotterdam Study as well as its RNA
expression profiles, methylation profiles, and all NGS data
including whole exome sequences, RNA sequencing, and
microbiome 16S sequencing.
Genome-wide association studies (GWAS) datasets
GWAS are based on genotyping epidemiological cohorts
with high density SNP arrays with 500,000 - 5 million
SNPs. The method has been shown to successfully identify
common genetic factors for hundreds of traits and diseases
(see www.genome.gov/GWAstudies). Through a large
grant from the Dutch research organisation NWO in 2007
one of the world’s largest GWAs datasets has been facili-
tated involving over 12,000 DNA samples from the Rot-
terdam Study cohorts. This GWAS dataset consists of a) a
small dataset of *450 women with 500 K Affymetrix
arrays (Nsp250 ? Sty250; the so-called pilot dataset), and
b) a large dataset of *12,000 samples covering almost all
RS-I, RS-II, RS-III DNA samples consisting of 550 K (RS-
I, II; single ? duo array format) and 610 K (RS-III; quattro
array format) Illumina array genotypes. In the pilot
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dataset also other array types have been run (including
Illumina Omniexpress 2.5) allowing for comparisons and
2-step imputation strategies to create local reference data
[404].
The Illumina GWAS dataset of the Rotterdam Study
(with approximately 500,000 SNPs having been geno-
typed) also forms the basis to generate so-called ‘‘imputed’’
datasets derived thereof. In this process the genotypes of
SNPs which have been genotyped in reference datasets
(such as HapMap with *8 million SNPs genotyped), are
being estimated for all Rotterdam Study samples using the
basis Illumina 500 K SNP dataset configurations in each
subject. With the advent of large reference datasets
becoming available based on whole genome/exome NGS,
imputation activities using the Rotterdam GWAS dataset
will remain an active area of development. So far, the
Rotterdam Study GWAS dataset has been imputed to
HapMap version 2 and 3 (with*7.5 million resulting SNP
genotypes in the Rotterdam Study dataset), and the 1000
genome dataset version 4 (with*18 million resulting SNP
genotypes in the Rotterdam Study dataset). Currently,
imputations are being generated for the Genome of the
Netherlands (GoNL) whole genome NGS dataset [405],
and the UK10 k whole genome sequencing dataset.
The Rotterdam Study GWAS dataset is actively being
used by all research lines within the Rotterdam Study as
can be read under the subheadings of each research line in
this review of the Rotterdam Study. In addition, it also
serves as a control GWAS dataset for other research groups
in- and outside The Netherlands for both SNP frequencies
as well as copy number variations (CNVs), in which
capacity it has been used in[ 100 publications up to date.
Most importantly, it has formed the start of a very suc-
cessful collaboration in the CHARGE consortium (com-
bining GWAS datasets of major epidemiological cohort
studies across the world) which has[50 phenotype work-
ing groups in which almost all research lines of the Rot-
terdam Study are active.
Candidate gene SNP studies
In the past, we have genotyped over 300 individual poly-
morphisms as part of candidate gene studies across the
complete Rotterdam Study cohort using Taqman and
Sequenom genotyping techniques. These mostly concern
individual potentially functional SNPs per gene (e.g.,
ApoE), but sometimes also haplotype tagging SNPs (e.g.,
ESR1, ESR2, HSD11B1, fibrinogen), and also high density
SNP screening (e.g., the vitamin D receptor gene). Cur-
rently, for candidate gene/SNP studies we perform look-
ups in the GWAS datasets and/or perform individual SNP
genotyping (e.g., SNPs not on the array, badly imputed
SNPs, functional SNPs).
RNA expression datasets
With the availability of good RNA from Rotterdam Study
participants, starting with the RS-III subjects, studies have
been initiated analysing the expression pattern of a single
gene across samples or of the complete RNA collection in a
sample (expression profiling). An expression profiling
dataset has now been generated for, ±900 samples of the
RS-III dataset, using the Illumina Human HT-12 v4 array
containing *48,000 probes. Subsequently, another set of
±900 samples have been subjected to RNA-sequencing
(see below) so that a very rich expression dataset of in total
±1800 samples is now available. While RNA expression is
known to differ between tissues, so far we only have RNA
isolated from whole blood as a tissue.
Methylation datasets
In the same samples that have RNA-expression profiles
(see above) we have also generated DNA methylation
profiles of *480,000 CpG sites across the human genome
using the Illumina Infinium HumanMethylation450 array.
As this same set of Rotterdam Study subjects was also used
for the RNA expression profiling, deep genomic studies
can now take place in combination with the GWAS data
and NGS data in these *1800 subjects.
New developments: next generation sequencing
datasets
A major development in genomics studies has been the
introduction in the past few years of high-throughput parallel
sequencing methods (also known as next generation
sequencing or NGS) which allow DNA (and RNA)
sequencing at unprecedented high speed and low costs. This
development has brought sequencing of whole genomes
within reach of individual laboratories, rather than the large
global effort that was needed to sequence the human genome
at first pass. This development has led to a revival in Men-
delian Genetics by solving many ‘‘cold cases’’ (because
causal mutations could directly be found in a few samples,
rather than by linkage analysis in many family samples and
laborious sequencing analyses of dozens of candidate gene
exons in the area). In addition, it has stimulated the cohort
studies that had generated GWAS datasets in the past 5 years,
to generate NGS data in part or all of their samples to find
local/regional variants of interest and variants that are very
rare. While whole genome sequencing (WGS) is often seen as
the ultimate goal in these efforts, currently almost all labs turn
to whole exome sequencing (WES) because it is much more
cost-effective. In WES the parts that code for amino acids as
part of the encoded proteins (i.e., the exons) are first captured
from the whole genome by hybridization techniques upon
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which the selected parts (the exons) are then subjected to
NGS. WES costs 5–10 times less euro’s than WGS (so, more
samples can be done with the same amount of money) and
generates interpretable findings. (note that for the vast
majority of areas in the human genome we have no good idea
what they signify as opposed to exons that encode function-
ally important parts, i.e., the parts that make up the proteins).
Whole exome sequencing dataset
A large grant from the NGI-sponsored Netherlands Con-
sortium for Healthy Ageing (NCHA), allowed to generate
WES NGS data for*3000 samples by the HuGe-F facility
on the Illumina HiSeq2000 sequencing machines. The
samples for this experiment were selected to constitutes a
random sample from the RS-I dataset. These NGS data have
been generated, and variants have been called. This process
is complicated and no golden standard exists, so these steps
take place together with colleagues at Baylor College, the
Broad Institute, and NGS facilities in Germany and
Netherlands, and is likely to be repeated several times in the
coming years when new software tools and data becomes
available. Through a collaborative grant from the NIH
Alzheimer initiative (ADSP) we will also obtain an addi-
tional*1000 samples with WES NGS data from RS-I. Also
here we collaborate with colleagues in CHARGE since NGS
data have been generated in large parts of the ARIC study,
the Framingham Study, and the CHS study. Within the
several working groups these data are currently being
analysed in relation to specific phenotypes.
From the first NGS efforts in reference datasets using
WES, many thousands of novel DNA sequence variants
were discovered in the exons, mostly rare to very rare and
not well-covered on the existing GWAS arrays. Illumina
and Affymetrix therefore decided to generate an array
devoted to analyse these new exome variants called the
Infinium HumanExome array. This array has been used to
genotype many DNA samples in the Netherlands (spon-
sored by BBMRI) and across the globe and several col-
laborative analyses are currently using data generated with
this array. In the Rotterdam Study we generated exome
array genotypes of*3000 samples of RS-I (with version 1
of this array), and this dataset is part of several collabo-
rative efforts, including the Dutch BBMRI exome array
effort (with *35,000 collective samples), an effort in
GIANT on anthropometric traits, and the CHARGE exome
array effort across many different phenotype working
groups (with *60,000 collective samples).
RNA sequencing dataset
In a large BBMRI-sponsored collaborative effort to create
a large-scale data infrastructure to work on integrative
omics studies in Dutch Biobanks, the Erasmus MC HuGe-F
genomics facility has generated RNA sequencing profiles
of in total ±4000 individuals of six Dutch biobanks,
including the Rotterdam Study. A total number of 900 RS-
samples were RNA-sequenced at a depth of 30 million
paired end reads. Together with colleagues at UMCG
Groningen and LUMC Leiden, the dataset was QC-ed and
annotated RNA-expression profiles were generated and
relations between genetics, transcriptomics, and epigenetic
measures are currently being analysed.
Microbiome 16S NGS dataset
Through applying NGS, it has recently become clear that
humans carry an astonishing variety and abundance of
micro-organisms (microbes, viruses, yeasts, unicellular
organisms) in and on their bodies, estimated to encapsulate
100-fold more cells than a human body counts. These
insights come from analysing diversity in 16S RNA
sequences which are species-specific for microbes, but also
from analyzing the complete microbial genomes through
much deeper so-called ‘‘meta-genomics’’ sequencing.
While microbes can be found almost everywhere in and on
the body, most studies have focused on analyzing faeces/
stool samples representing the microbial flora in the (last
part of the) intestinal system. Sofar, this knowledge has
come from very small studies with limited phenotype
information outside an epidemiological setting. While the
latter approach of meta-genomics is (10–209) more
expensive and generates vast amounts of data with con-
committant challenges in mapping and data-analysis, most
epidemiological studies focus now on establishing 16S
datasets and mostly derived from stool. HuGe-F has opti-
mized stool collection protocols to be applied in epidemi-
ological settings (collection at home, shipment by mail),
and has introduced and optimized 16S sequencing proto-
cols (NGS of the 16S v3/v4 area). Within the Rotterdam
Study RS III, we have collected*1700 stool samples from
which DNA has been isolated and which are currently
subjected to 16S v3/v4 NGS analysis. For other source of
microbiomes (eye, urine, mouth, skin, etc.) several pilot
projects are ongoing to establish feasibility.
New developments: integrative genomics
GWAS have identified a large number of genetic risk
markers for many diseases and traits over the last decade.
The Rotterdam Study has been part of many of those dis-
coveries. However, because most variants and their proxies
are non-coding, it is generally difficult to identify the
causal genes. Integrative genomic studies can help to
identify functional mechanisms underlying the genetic
associations found. By combining genetic, transcriptomic,
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and epigenetic data, driving disease mechanisms can be
identified. Similarly this can be done for analyzing
microbiomes in this context of genetic susceptibility and
genomic variables and risk factors.
Within the Rotterdam Study, novel epigenetic and
transcriptomic datasets have been generated in large sub-
sets of the study (see above) and transcriptomic data
(RNAseq/array)). Part of this data is acquired within the
BIOS consortium which is rainbow project funded by
BBMRI-NL to create a large-scale data infrastructure and
to bring together BBMRI researchers focusing on integra-
tive omics studies in Dutch Biobanks. Using this data, we
performed the largest expression quantitative trait locus
(eQTL) meta-analysis so far reported in non-transformed
peripheral blood samples, including replication. We iden-
tified multiple trait-associated SNPs (diabetes, cholesterol,
SLE) that affect multiple trans-genes, and identified novel
insights into these associations (PMID: 24798236). Toge-
ther with collaborators from UMCG Groningen, we iden-
tified cell-specific eQTL within whole blood RNA
expression data without having to sort cells [406]. By
studying gene expression signatures of blood pressure, we
provided new insights into molecular mechanisms under-
lying BP regulation [407].
As part of a second rainbowproject of BBMRI a total
2981 samples has been characterized for 232 metabolites at
Brainshake’s Biomarker Analysis Platform (http://www.
brainshake.fi/). The sample included all participants of
RSI-4 (N = 2807) and 79 of RSII-2, 2 of RSII-3 and 87 of
RS3-2.The metabolites comprise of small molecular com-
pounds and lipoproteins subfractions.
For additional EJE references see [22, 26, 27, 149, 408–
424].
Pharmaco-epidemiologic studies
Objective
In the Rotterdam Study, the role of drugs is studied as
determinant of diseases in middle-aged and older com-
munity-dwelling individuals. This includes studying effi-
cacy and effectiveness of drugs, as well as adverse
reactions to drugs. As the drugs used in the Rotterdam
Study are licensed and often on the market since several
years, research focuses on determinants which modify the
safety and effectiveness of widely used drugs because these
often have a great impact on healthcare.
Major findings
Below, we summarize findings over the most recent period.
These findings can be distinguished into three topics of
special interest, i.e. genetic and other determinants of
effectiveness and adverse effects of statins; cardiac rhythm
disorders and sudden cardiac death; and miscellaneous
pharmaco-epidemiologic topics of interest in the Rotter-
dam Study.
Statins
The increasing incidence and prevalence of cardiovascular
disease (CVD) constitutes a considerable disease burden.
CVD frequently co-exists with other diseases such as type
2 diabetes mellitus (T2DM) and non-alcoholic fatty liver
diseases (NAFLD), which are both strongly related to the
metabolic syndrome. Statins are cholesterol-lowering drugs
that are beneficial in the primary and secondary prevention
of CVD. With an approximately 20–25 % reduction of the
risk of major cardiovascular endpoints, these drugs have
definitely entered daily clinical practice. However, some
individuals may not respond adequately to statins, and non-
compliance can be a problem [425]. In 2013, the American
ACC/AHA guidelines on primary prevention of CVD
lowered the threshold for the indication for statin treat-
ment. According to these guidelines, we analysed in the
Rotterdam Study how many people would have had an
indication for statins. The ACC/AHA guideline would
recommend statins for nearly all men and two-thirds of
women of the Rotterdam Study, proportions exceeding
those according to the ATP-III or ESC guidelines [32].
This somewhat unbelievable result shows how fast and
irresistible medicalization of Western society progresses.
We investigated genetic variation that modified the effi-
cacy and effectiveness of statins, and their risk of adverse
drug reactions in clinical practice. We used the hypothesis-
free genome-wide association (GWAS) approach to discover
new genetic markers without a priori hypothesis of the
underlying genetic variation, and the candidate gene
approach to replicate genetic variation that has previously
been associated with a modified statin response or occurred
in a pathway that relates to statin pharmacokinetics [425].
We investigated the LDL-cholesterol lowering response to
statins in a GWAS, as part of the GIST consortium including
more than 40,000 statin users in both randomized controlled
trials and observational studies. In this large pharmacoge-
netic meta-analysis, two loci at Sortilin 1 (SORT1) and
SLCO1B1 were newly discovered to be associated with a
stronger, and decreased LDL-cholesterol lowering response
to statins, respectively. Furthermore, previously described
associations with Apolipoprotein E (APOE) and Lipopro-
tein, Lp(a) (LPA) were confirmed, that showed a stronger
and decreased LDL-cholesterol lowering response, respec-
tively [426]. In three candidate gene studies, we investigated
the influence of genetic polymorphisms on the cholesterol-
lowering response to statins. First, we investigated the role
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of genetic variation in genes involved in cholesterol meta-
bolism. We selected polymorphisms in these genes based on
a hypothesis-free approach, and subsequently tested the
most promising ones in a candidate gene analysis. We
showed that two polymorphisms in two different genes,
rs1532624 in the cholesteryl ester transfer protein (CETP)
gene and rs533556 in the apolipoprotein A-I (APOA1) gene,
were associated with a decreased cholesterol lowering
response to statin therapy. The association for the CETP
polymorphism was subsequently replicated in an indepen-
dent population [427]. Second, we were the first study that
demonstrated that two strongly linked polymorphisms in the
peroxisome proliferator- activated receptor (PPARA) gene,
rs4253728 and rs4823613, were associated with a stronger
cholesterol lowering response to statins. Thereby, we con-
firmed a pharmacokinetic mechanism which was previously
discovered, i.e. that these two polymorphisms were associ-
ated with significantly decreased cytochrome P450 3A4
(CYP3A4) enzyme expression and activity [428]. Third, we
performed a first replication of a recent finding that the
rs13064411 polymorphism was associated with increased
statin-induced serum proprotein convertase subtilisin/kexin
type 9 (PCSK9) concentrations, and cholesterol response to
statins. PCSK9 binds to the low-density lipoprotein (LDL-)
receptor, and subsequently promotes the receptor for
degradation. We showed that the rs13064411 polymorphism
was associated with a decreased cholesterol lowering
response to statins, and this effect was stronger in women
and in users of a high dose of statins [429]. The risk of MI is
indirectly influenced by statins via cholesterol lowering, but
is also influenced by underlying diseases, such as hyper-
tension and T2DM. The heterogeneity in causal risk factors
for a hard clinical endpoint such as myocardial infarction
(MI), may affect the probability of detecting one specific
gene-statin interaction and may therefore require more
power than with an intermediate endpoint. The CYP3A4*22
polymorphism, previously associated with a stronger
cholesterol lowering response to statins, was based on the
magnitude of its effect on cholesterol, a good candidate to
investigate on the outcome MI. However, we could not
demonstrate significant effect modification by the
CYP3A4*22 polymorphism on the effect of statins in
reducing the risk of MI, neither in the independent UCP
study and Rotterdam Study separately, nor in a meta-anal-
ysis of the two studies [430]. In patients with a body mass
index (BMI) C27.5, current use of statins for more than
2 years was significantly associated with an approximately
three times lower NAFLD prevalence [247].
In general, statins are safe and well-tolerated drugs,
although a common ADR is myopathy, which can vary
from myalgia to life-threatening rhabdomyolysis. We
confirmed the previously described association between the
rs4149056 c.521T[C polymorphism in the solute carrier
organic anion transporting polypeptide (SLCO1B1) gene
and an increased risk of developing ADRs to statins. In
simvastatin users in the Rotterdam Study, we demonstrated
that the rs4149056 polymorphism was associated with an
increased risk of a dose decrease or switch to another
cholesterol lowering drug, as indicators for ADRs. For
atorvastatin users, an association was found in users with a
starting dose of more than 1.00 standardized defined daily
dose [431]. In another analysis in the Rotterdam Study,
current use of statins was associated with lower total and
(bioactive) non-sex hormone-binding globulin (SHBG)-
bound testosterone levels in males. Statins decrease
cholesterol production, and cholesterol is a precursor in the
testosterone biosynthesis pathway. This association might
be clinically relevant, given the important biological role of
testosterone, the increased use of statins, and the fact that a
modest average decrease in a population might hide a
substantial decrease in a handful of individuals and in those
with an already low testosterone level [432].
Drug-induced rhythm disorders and sudden cardiac death
A prolonged QT interval is an important risk factor for
ventricular arrhythmias and sudden cardiac death. In an
analysis in the Rotterdam Study over the 20-year period
1990–2010, a declining incidence of sudden cardiac death
was observed [433]. QT prolongation can be caused by
drugs, but also other factors, such as genetic variants are
important for the occurrence of QT prolongation. A genetic
association study of QT interval highlighted a role for
calcium signalling pathways in myocardial repolarization
[434]. QT prolongation is one of the most common reasons
for withdrawal of drugs from the market, despite the fact
that these drugs may be beneficial for certain patients and
not harmful in every patient. Identifying genetic variants
associated with drug-induced QT prolongation might add
to precision medicine and prevent beneficial drugs from
being withdrawn unnecessarily. We reassessed the associ-
ation between tricyclic antidepressants (TCAs) and pro-
longation of the QT interval. The rationale of this study
was that the heart-rate corrected QT interval (QTc) cal-
culated with Bazett’s formula is overestimated in users of
anticholinergic drugs, which also include the TCAs. In our
study population, we observed that the use of TCAs was
associated with a longer QTc as calculated with Bazett’s
formula. However, when other correction methods were
used or heart rate was included as an additional covariable
in the statistical model, no association between use of
TCAs and QTc was observed [435]. We also assessed the
association between individual SSRIs and QTc prolonga-
tion. Of the individual SSRIs, only citalopram use was
associated with a prolonged QTc in our study. Even though
regulatory authorities restricted the use of citalopram to
686 A. Hofman et al.
123
20 mg in patients 60 years and older, participants aged
60 years and older in our study using citalopram dosage
with a daily dose of more than 20 mg had a longer QTc.
Although our study had a limited number of citalopram
users, this study may rise questions about the safety of
citalopram in high-risk patients populations (e.g., elderly)
[436]. A new potentially interesting risk factor for sudden
cardiac death is QT variability [437].
A second important rhythm disorder is atrial fibrillation
with its high prevalence and potential cerebrovascular
consequences. In the Rotterdam Study, we were able to
confirm earlier work on the association between use of
non-steroidal anti-inflammatory drugs (NSAIDs) and atrial
fibrillation [438] and its association with hypokalemia
[439]. As important potential effect modifier, we partici-
pated in a collaborative study demonstrating several new
risk variants for atrial fibrillation [440].
Miscellaneous topics of pharmaco-epidemiologic interest
Over the last decades, antidepressant drug use increased in
Western countries, including in the Netherlands. Older
adults using antidepressant drugs deserve special care, as
they often have a slower metabolism of drugs, impaired
renal function, more co-morbidity, and more concomitantly
used medications. We investigated the utilization of
antidepressants in the Rotterdam Study over the period
1991–2011. The yearly prevalence of antidepressant use
increased from 3.9 % in 1991 to 8.3 % of the population in
2011. The increase in SSRI use was 5.8-fold, whereas use
of other antidepressants doubled and TCA use remained
stable over time. The incidence of all antidepressants
decreased from 23.9 to 14.2 per 1000 person-years between
1992 and 2011. The duration of a first treatment episode
increased over time [441]. In a further study, we demon-
strated an association between genetic variation in the
ABCB1 gene and switching, discontinuation, and dosage of
antidepressant therapy: results from the Rotterdam Study
[442].
Several studies have been associated with haemorrhagic
strokes, notably coumarins and other anticoagulants and
aspirin but less is known about an association with cerebral
microbleeds on MRI. In the Rotterdam Study, we investi-
gated the association with several drugs. Use of serotonin
reuptake inhibiting antidepressants was not related to
presence of cerebral microbleeds [443]. Compared with
never users, coumarin users had a higher prevalence of
deep or infratentorial microbleeds and a higher incidence
of any microbleeds, although statistical significance was
not reached in the latter. A higher maximum INR was
associated with deep or infratentorial microbleeds. Among
coumarin users, a greater variability in INR was associated
with a higher prevalence of microbleeds [444]. In stroke-
free individuals, clopidogrel use was associated with a
higher prevalence and higher number of microbleeds [445].
In further studies, it was demonstrated that chronic use of
coumarin anticoagulants is associated with renal function
decline [446]. Although thiazide diuretics are a well-known
cause of hyponatremia, hypokalemia is also common
[447]. Cardioselective beta-blockers were developed to
prevent respiratory adverse effects, also these drugs are
associated with a decreased pulmonary function [397]. In a
large international consortium meta-analysis, no associa-
tion could be demonstrated between pioglitazone and
bladder cancer [448].
New developments
Most new pharmaco-epidemiologic developments nowa-
days are associated with pharmacogenomics, proteomics
and metabolomics. In an international collaborative study,
we used tissue-specific quantitative interaction proteomics
to map a network of five genes involved in the Mendelian
disorder long QT syndrome (LQTS). We integrated the
LQTS network with GWAS loci from the corresponding
common complex trait, QT-interval variation, to identify
candidate genes that were subsequently confirmed in
Xenopus laevis oocytes and zebrafish. We used the LQTS
protein network to filter weak GWAS signals by identify-
ing single-nucleotide polymorphisms (SNPs) in proximity
to genes in the network supported by strong proteomic
evidence. Three SNPs passing this filter reached genome-
wide significance after replication genotyping [449]. As
part of methodology development, we used multiple cross-
sectional assessments of depressive symptoms in a popu-
lation-based study to identify potential genetic interactions
with SSRIs as a model to study genetic variants associated
with SSRI response. We used repeated measurement
models to test multiplicative interaction between genetic
variants and use of SSRIs on repeated CESD scores.
Besides a genome-wide analysis, we also performed an
analysis which was restricted to genes related to the sero-
tonergic signalling pathway [450]. Furthermore, we
demonstrated the potential for increased power using GEE
analyses instead of cross-sectional analyses. To illustrate
methods for detection of gene-drug interactions on a gen-
ome-wide scale, using repeated measures data, we conduct
single-study analyses and meta-analyses across studies in
three large cohort studies participating in the CHARGE
consortium [451].
In the field of statistical modelling of drug exposure
data, we extended our previous work on analysing drug use
as a time-dependent exposure [452]. We performed a study
in which the association between statins and cardiovascular
endpoints was analysed with marginal structural modelling
[453].
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For additional EJE references see [10, 126, 128, 142,
240, 453–468].
Imaging studies
Objective
Biomedical imaging allows for non- or minimally-invasive
assessment of structural and functional changes that may
reflect specific pathology. Recent developments in image
data acquisition and analysis enable to use these techniques
on a large scale. The Population Imaging Unit within the
Rotterdam Study aims to assess imaging biomarkers of
disease in a pre-symptomatic phase at the population level.
Advantages of imaging measures include that they mark
early disease, can be assessed reliably and reproducibly,
and are quantitative rather than qualitative which makes
them more powerful than most conventional outcome
measures such as clinical phenotypes.
The main imaging modalities that are currently being
applied in the Population Imaging Unit are multidetector
computed tomography (MDCT) and magnetic resonance
imaging (MRI).
Imaging infrastructure and storage
MDCT
CT imaging is performed with hospital-based 16- or
64-slice MDCT scanners (SOMATOM Sensation 16 or 64,
Siemens, Forcheim, Germany), located at Erasmus MC.
Scanners are operated by clinical technicians. CT images
are acquired without contrast-enhancement and according
to standardized protocols. Imaging data are transferred
from the CT scanner to a securely backed-up research
picture archiving system.
MRI
From August 2005 onwards, a dedicated 1.5 T MRI scan-
ner (GE Healthcare, Milwaukee, WI, USA) is operational
in the Rotterdam Study research center. This scanner is
operated by trained research technicians and all imaging
data are collected according to standardized imaging pro-
tocols. Changes or updates in hardware or software con-
figuration are avoided and regular quality checks are
performed to secure validity of cross-subject and cross-
scan comparisons. Imaging is performed without adminis-
tration of contrast agents. All imaging data are directly
transferred from the scanner facility to the Erasmus MC.
Data are stored on a securely backed-up research picture
archiving system, using programmed scripts to check for
completeness of the data received.
Data management and processing
Assessment of incidental findings
All imaging data are visually evaluated within days after
acquisition by trained physicians for the presence of clin-
ically relevant incidental findings [274]. Expert radiologists
are consulted for all abnormal findings and the manage-
ment of clinically relevant findings is based on protocols
defined by expert panels. These protocols are updated on a
regular basis incorporating the current best available
knowledge regarding treatment and prognosis of the vari-
ous abnormalities discovered. We are furthermore actively
collaborating with ethical, legal and medical stakeholders
to design a framework for the management of incidental
findings that can be used both nationally and internation-
ally for population-based imaging.
Automated processing of MRI data
Though some measurements are still performed manually
or scored visually, the majority of imaging data is now
processed using semi- and fully-automated computer
algorithms. The Population Imaging Unit collaborates with
the Biomedical Imaging Group Rotterdam (BIGR) of
Erasmus MC in the application and development of auto-
mated processing pipelines for high-throughput of large
data quantities. These pipelines comprise on the one end
image quality checks and procedures for non-uniformity
correction, normalization and image registration and on the
other end advanced algorithms to extract image features to
use for analyses.
Grid architectures and networked processing pipelines
are used to process the large quantities or imaging data that
are acquired in the Rotterdam Study.
Major findings
The Rotterdam Study research lines currently applying
imaging within the Population Imaging Unit are those on
neurological diseases and cardiovascular diseases.
Brain imaging (MRI)
Neurodegenerative and cerebrovascular disease are com-
mon disorders in the elderly that exert a large influence on
brain functioning. Identifying underlying pathology in a
preclinical state may help to recognize persons at risk,
assess determinants of disease and develop preventive
measures. Main objective for the Population Imaging Unit
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with respect to brain imaging is therefore to identify and
quantify brain imaging biomarkers that mark the develop-
ment of neurodegenerative and cerebrovascular disease.
From August 2005 onwards (RS-II-2 and onwards),
brain imaging in the Population Imaging Unit is performed
in all study participants without contra-indications in the
context of the Rotterdam Scan Study. The current structural
scanning protocol includes 4 high-resolution axial
sequences (3D T1-weighted; 2D PD-weighted; 2D FLAIR;
and 3D T2* GRE), 2D phase-contrast imaging, and diffu-
sion tensor imaging (DTI). Total scanning time for these
sequences amounts to approximately 30 min. Currently,
over 5,800 unique brain MRI scans and over 6,300 follow
up scans have been acquired with this protocol. Starting
2012, functional imaging has been incorporated in the MRI
protocol in the form of a resting-state fMRI sequence
(8 min), which was added to the existing structural scans.
To date, rs-fMRI scans have been acquired in over 2,000
individuals and this is ongoing.
Fully automated methods are applied to quantify atrophy
of brain tissues and structures and the severity of white
matter lesions [294, 469, 470]. Automated hippocampal
segmentation has been successfully applied on multi-
scanner acquired MR images (on scans acquired in the
Rotterdam Scan Study in 1995 [288] and follow up
examinations in 2006), showing that a decline in hip-
pocampal volume over a 10-year follow up period pre-
dicted onset of clinical dementia [471]. Apart from
focusing only on supratentorial brain structures, we have
also incorporated segmentation of the cerebellar volume
into our automated processing pipelines, enabling us to
study the cerebellum in aging.
Phase-contrast imaging allows for assessment of blood
flow in the carotids and basilar artery. This yields measures
of total brain perfusion [472], which when lower was found
to be relate to worse cognition, an association that is
mediated by brain atrophy [473]. More recently, we used
our longitudinal imaging data to address the ongoing
debate whether reduced perfusion causes brain atrophy or
vice versa, and found that brain volume reduction relates to
decrease in perfusion over time, presumably through lower
metabolic demand [474].
The 3D T2* GRE sequence that we use was specifically
developed to increase the conspicuity of cerebral microb-
leeds [475]. With this optimized sequence, we found that
microbleed prevalence gradually increases with age, from
6.5 % in persons aged 45 to 50 years to 35.7 % in partic-
ipants of 80 years and older; and that overall, 15.3 % of all
subjects over the age of 45 years has at least 1 microbleed;
a much higher prevalence than was reported before [476,
477]. We found supportive evidence that deep or
infratentorial microbleeds reflect arteriolosclerotic
angiopathy, whereas strictly lobar microbleeds are caused
by cerebral amyloid angiopathy [476, 477]. We further-
more demonstrated that incidence of microbleeds over a
3-year time interval is high and that risk factors for new
microbleeds again differ according to microbleed location,
in line with our findings regarding prevalent microbleeds
[478]. These findings impact research into the causes of
cerebral amyloid angiopathy, as well as fuel the ongoing
discussion about the safety of antithrombotic therapy in
persons with microbleeds [444, 479, 480]. Our most recent
studies focus on the interplay between haemorrhagic and
ischemic imaging markers [481], pointing towards a shared
etiologic pathway. This is further supported by our finding
that microbleeds relate to an increased risk of stroke, both
ischemic and haemorrhagic, over a mean follow up of five
years [482]. Diffusion tensor imaging (DTI) allows the
assessment of the microstructural integrity of white matter.
White matter microstructure loses its integrity with
increasing age, but this can largely be explained by pres-
ence of white matter atrophy and white matter lesions
[483]. Nevertheless, the microstructural integrity in the
normal appearing white matter and in white matter lesions
relates to cognitive function regardless of concurrent
macrostructural changes, emphasizing the importance of
the microstructural integrity of white matter [484]. Also,
we found that white matter changes in normal appearing
white matter are present and can be quantified on diffusion
tensor imaging before white matter lesions actually
develop. This suggests that white matter lesions develop
gradually, and that visually appreciable lesions are only the
tip of the iceberg of white matter pathology. We developed
within the Rotterdam Study a method for fully automated
tractography of over 20 major white matter tracts, yielding
tract-specific measures of white matter integrity, enabling a
more in-depth exploration of structural integrity in relation
to functional processes in aging [485]. Using these tract-
specific measures, we could demonstrate widespread
deterioration of white matter integrity with age, which
nevertheless showed variations across tract groups, with
the motor system being relatively spared [486]. We are
currently extending this work to assess longitudinal chan-
ges in white matter integrity and tract-specific influences
on cognitive function.
Imaging of atherosclerotic calcifications (MDCT)
Main objectives with respect to imaging of vascular cal-
cifications are to investigate distribution of and risk factors
for atherosclerotic calcifications in the general elderly
population and to study prognosis associated with calcifi-
cations in different vessel beds.
From September 2003 until February 2006, all partici-
pants from RS-I-4 and RS-II-2 who completed a center
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visit were invited to a MDCT scan of the coronary arteries
and a second scan of the aortic arch and carotid arteries. A
total of 2521 participants (response rate 79 %) were
scanned. The cardiac scan reached from the apex of the
heart to the tracheal bifurcation. The second scan reached
from the aortic arch to the intracranial circulation. Images
were analysed by trained reviewers and calcification in the
different vessel beds (coronaries, aortic arch, extracranial
and intracranial carotids) were quantified using the Agat-
ston score [487].
As expected, we found that calcification load was higher
overall in men compared to women, though aortic arch
calcification was more prevalent among women [488]. Age
and current smoking were found to be the strongest inde-
pendent risk factors for arterial calcification [489]. Fur-
thermore, strong and graded associations of prevalent
stroke were found with carotid artery, aortic arch and
coronary artery calcification, independent of cardiovascular
risk factors [490]. When vessel calcification was studied in
relation to vascular brain disease (non-invasively imaged
with MRI), we found that larger intracranial carotid cal-
cification load related to larger white matter lesion load,
and that larger extracranial carotid calcification load rela-
ted to the presence of cerebral infarcts, independently of
ultrasound carotid plaque score. This suggests that calci-
fication of atherosclerotic plaque yields other information
in addition to merely the presence of plaques. This
importance of vessel calcification is further corroborated
by our recent finding that larger calcification volumes are
associated with worse cognitive performance in the general
population [276].
Despite extensive research on the identification of life-
style- and environmental cardiovascular risk factors, a
large part of the variability in the total burden of
atherosclerosis remains yet unexplained. This inevitably
indicates that other, unknown factors also considerably
contribute to the development of atherosclerosis. During
the last years, it has become clear that genetic factors may
play an important role in the development of atheroscle-
rosis. We determined whether previously identified genetic
loci for coronary calcification were also associated with
calcification in other locations than the coronary arteries
Indeed, we found that the genetic basis for aortic arch and
carotid artery calcification largely overlaps with that of
coronary artery calcification. However, we found that the
genetic variants contributed differentially to the amount of
atherosclerotic calcification in these vessel beds. This
suggests that also on the genetic level, differences in the
etiology of atherosclerosis across vessel beds exist. Addi-
tionally, we also investigated the genetic basis of
atherosclerosis using the genetics of strong risk factors of
atherosclerosis, i.e. serum cholesterol levels and blood
pressure and demonstrated that both serum lipids and blood
pressure share a genetic predisposition with the formation
of atherosclerosis in multiple vessel beds.
Worldwide, intracranial atherosclerosis is one of the
leading causes of stroke, yet it is understudied in popula-
tion of white descent. We therefore focused specifically on
the prevalence and risk factors of intracranial internal
carotid artery calcification in our population, and found
that the overall prevalence of intracranial atherosclerosis
was as high as 82.2 %. Conventional cardiovascular risk
factors are associated with intracranial atherosclerosis, but
risk factor profiles differed between men and women, with
excessive alcohol intake and smoking were strong risk
factors in men, whereas diabetes and hypertension were in
women. We were the first to demonstrate in this general
population-setting, that intracranial atherosclerosis is also a
major cause of stroke in whites [491]. Even after adjust-
ments for large-artery atherosclerosis in the aortic arch and
the carotid artery bifurcation, this relationship was firmly
present. Moreover, we found that intracranial atheroscle-
rosis contributed to 75 % of all strokes, whilst for aortic
arch atherosclerosis or atherosclerosis in the carotid artery
bifurcation this was 45 and 25 %, respectively. Altogether,
these findings emphasize that existing location-specific
differences in atherosclerotic burden indeed translate into
differences in risk of subsequent cerebrovascular disease.
With our study on atherosclerosis and the risk of
dementia, we further established the role of atherosclerosis
in the etiology of dementia [276]. Most importantly, we
found that systemic atherosclerosis was associated with a
higher risk of dementia and cognitive decline. Actually,
this suggests that generalized atherosclerosis, which prob-
ably is a better reflection of one’s vascular status rather
than localized atherosclerosis in a single vessel bed, asso-
ciates with dementia.
Carotid plaque imaging (MRI)
Carotid wall thickening and atherosclerosis are highly
prevalent at older age and are considered a major cause of
cerebrovascular events [268]. Carotid atherosclerotic pla-
que constituents such as lipid core and haemorrhage, so-
called ‘‘vulnerable’’ components, are considered important
factors in development of clinical neurological events
[492]. With MRI, it is possible to separately identify these
plaque components [493]. Main objectives with respect to
carotid imaging in the Rotterdam Study are to investigate
distribution of and risk factors for carotid plaque compo-
nents in the general elderly population and to study prog-
nosis associated with specific carotid plaque composition.
From October 2007 onwards, all participants with car-
otid wall thickening of 2.5 mm or larger on ultrasound
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(approximately 25 % of the Rotterdam Study population)
are invited for carotid MRI. Imaging is performed with a
bilateral phased-array surface coil (Machnet, Eelde, the
Netherlands), stabilizing subjects in a custom-designed
head holder to reduce motion. The imaging protocol con-
sists of a series of high-resolution MRI sequences to image
the carotid bifurcations on both sides: a PDw Fast Spin
Echo (FSE) Black-blood (BB) sequence; a PDw-FSE-BB
with an increased in-plane resolution; a PDw- Echo Planar
Imaging (EPI) sequence and a T2w-EPI sequence; and 2
three-dimensional (3D) sequences: a 3D-T1w-Gradient
Echo (GRE) sequence; and a 3D phased-contrast MR-
Angiography. Total scanning time amounts to approxi-
mately 30 min.
Plaques are reviewed by trained raters for the presence
of three different plaque components (calcification, haem-
orrhage and lipid core). Furthermore, carotid plaque size is
quantified by obtaining maximum carotid wall thickness
and degree of luminal stenosis using the NASCET criteria
[494] on the PDw-FSE images. Postprocessing techniques
aimed at automated quantification of plaque volume and
identification of different plaque components are currently
being developed.
So far, close to 2000 participants underwent a complete
carotid MRI scan and data are currently being analysed.
There is a complete overlap between carotid and brain MRI
participants, allowing for the investigation of carotid pla-
que constituents in relation to brain imaging markers. In
the first 1,006 scans, we found that intraplaque haemor-
rhage and lipid core were present in almost 25 % of pla-
ques, respectively, and occurred simultaneously in 9 % of
plaques. Different risk factors are associated with these
plaque components: hypertension (and in particular high
pulse pressure) and current smoking were risk factors for
the presence of intraplaque haemorrhage, and hyperc-
holesterolaemia was the only risk factor for lipid core
presence.
Ischemic strokes are more often diagnosed in the left
hemisphere than in the right, therefore we hypothesized
that asymmetry in carotid atherosclerosis may play a role in
this observation.
We indeed demonstrated that plaque prevalence, sever-
ity and composition are not equally distributed among the
left and right carotid arteries [495]. Left-sided plaques were
slightly thicker than the contralateral side and were pre-
dominantly composed of IPH and fibrous tissue. These
findings suggest that atherosclerotic plaques on the left are
more vulnerable than on the right.
Using the strength of both CT and MRI data in a sub-
sample of our population, we were able to assess the
relationship between calcification, intraplaque
haemorrhage and lipid core within the carotid atheroscle-
rotic plaque [496]. Plaques with a higher load of calcifi-
cation contain more often haemorrhagic components, but
less often lipid core. These findings suggest that a higher
load of calcification does not imply that a plaque is more
stable, and urge for prospective studies investigating the
interrelation of these different plaque components with
regard to future cerebrovascular events.
New developments
As also mentioned above, focus has shifted from purely
structural imaging to also including functional imaging
data, by incorporating resting-state functional MRI into the
brain imaging protocol. Changes in the intrinsic activity of
resting-state networks are presumed to represent alterations
in functional brain connectivity and may mark neurode-
generation in an early, presymptomatic stage. Our initial
studies will focus on the relation between functional brain
connectivity and established structural markers in age-re-
lated brain diseases such as hippocampal volume, white
matter lesions and microbleeds. In a later stage, we will
investigate whether functional connectivity can be used an
early imaging marker for dementia, by itself or in combi-
nation with other imaging markers and risk factors.
Regarding structural imaging markers, an emerging
potential marker is Virchow–Robin (VR) spaces, spaces
filled with interstitial fluid that surround the blood vessels
in the brain and which can be dilated. Despite increasing
literature on these dilated VR spaces, a major limitation of
current research is the lack of a robust and generalizable
rating method on MRI. Within the Rotterdam Study, we
developed a novel rating method for VR spaces, which we
successfully applied in 2 population-based studies,
encompassing 3 different scanning protocols. We are now
using this rating method to explore determinants and con-
sequences of dilated VR spaces in our general aging pop-
ulation, as well as in a larger consortium of other clinical
and population studies (www.uconsortium.org).
Besides ever-increasing advances in imaging hardware,
software and sequence design, major advances in the short
and long run are to be expected from (fully) automated
image analysis. Computer processing of images will enable
to make fully use of all information contained within the
image, introducing new imaging biomarkers. Besides, the
vast amount of imaging data that are acquired in popula-
tion-based studies like the Rotterdam Study renders visual
assessment or manual measurements virtually impossible,
strengthening the need for (fully) automated methods of
data extraction and analysis.
For additional EJE references see [13, 400, 497–500].
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Otolaryngological diseases
Objectives
Otolaryngological research in the Rotterdam Study focuses
on the frequency, etiology and consequences of auditory
and vestibular disorders. We are mainly interested in dys-
functions located in the labyrinth of the inner ear, expres-
sed by cochlear hearing loss and a deviant vestibulo-ocular
reflex (VOR) for fast head movements. Etiology of both
peripheral disorders will be studied, possibly revealing one
or more common risk factors as both systems are connected
and have similar sensory mechanisms. Additionally, we
will investigate the consequences of reduced sensory input
on brain development and function.
Methods
Data on both hearing and vestibular function have been
collected in the cohorts RS-II-3and RS-III-2. Hearing data
has also been collected in RS-I-5. Hearing loss is assessed
at both ears by performing pure-tone audiometry in a sound
proof room. Hearing thresholds are determined with
headphones at frequencies 0.25, 0.5, 1, 2, 4 and 8 kHz. To
distinguish between cochlear and middle-ear pathology,
also bone-conduction thresholds are measured at frequen-
cies 0,5 and 4 kHz. Additionally, speech perception in
noise is tested at the better ear, using a validated triplet
digit test [501] with speech-shaped noise at a fixed pre-
sentation level. The ability to understand speech in noise is
a functional measure that includes both sensory and central
aspects of the auditory system.
Peripheral vestibular function is assessed by The Head
Impulse Test (HIT), which measures the vestibule-ocular
reflex (VOR) for a number of sudden head movements
initiated by the tester [502]. Gain and delay are the main
parameters that will be used to quantify vestibular function.
An advanced infrared video-oculography system is used to
track the eye movements simultaneously with the position
of the head, enabling VOR recordings, even for fast head
movements. Additionally, central vestibular processing is
assessed by measuring the VOR during repetitive slow
head movements at frequencies 0.5, 1 and 2 Hz while
fixating the eyes at a projected visual target. The oculo-
motor function is tested by eye tracking of a moving target
at frequencies 0.5, 1 and 2 Hz, while the head is fixated
(the smooth pursuit).
The general interview contains ten questions related to
hearing and balance problems. In case of hearing-aid use,
the participant has to answer five additional questions of
the International Outcome Inventory of Hearing Aids (IOI-
HA) [503]. In case of frequent tinnitus, ten additional
questions of the Short Tinnitus Handicap Inventory (THI-
S) are added [504].
Determinants of interest
One of our main goals is to find medical and genetic factors
that are associated to age-related hearing loss. Age-related
hearing loss is a common disorder that deprives older people
of key sensory input. It leads to social withdrawal [505] and
is even been found to be independently associated with
poorer cognitive functioning and incident dementia [506,
507]. Still, little is known about the mechanisms that are
responsible for developing hearing loss and the way it
affects general cognitive functions within the elderly popu-
lation. Determinants of interest are genetic factors, cardio-
vascular disease, use of medication, endocrine diseases and
neuroepidemiological factors. Analyses of genetic risk fac-
tors will be performed in close collaboration with other
groups within the CHARGE consortium.
Even less is known about age-related vestibular dys-
function. Problems related to balance and dizziness are
frequently reported in elderly people, but there is still
uncertainty about the prevalence and type of vestibular
dysfunction that may cause these problems [508]. This is
one of the first large cohort studies in which vestibular
function will be measured. The aforementioned determi-
nants for hearing will also be studied for the vestibular
system. Additionally, the relation between hearing and
peripheral vestibular function will be extensively
investigated.
Major findings
In order to have sufficient statistical power and age cov-
erage we combined the data collection of RS-II-3 and RS-
III-2. First data analyses on hearing have been completed
and main outcomes will be published in near future. In
general, hearing loss is highly prevalent within the tested
group. We found a hearing loss of 20 dB HL or higher in
more than 50 % of the people. The amount of hearing loss
is higher in men than in women, although the difference is
smaller than previously reported and presented by the
current clinical standards. As expected, hearing loss is
strongly associated with age and leads to a poorer under-
standing of speech in background noise.
Management
The Rotterdam Study is directed by a Management Team
comprising the scientific principal investigators Sarwa
Darwish Murad (PI Hepatic diseases), Cornelia van Duijn
(PI Genetic epidemiologic studies), Oscar Franco (PI
692 A. Hofman et al.
123
Cardiovascular diseases), Andre´ Goedegebure (Otolaryn-
gological diseases), Albert Hofman (chairman, PI Rotter-
dam Study), Arfan Ikram (PI Neurological diseases),
Caroline Klaver (PI Ophthalmic diseases), Tamar Nijsten
(PI Dermatological diseases), Robin Peeters (PI Internal
Medicine), Bruno Stricker (PI Pharmaco-epidemiology),
Henning Tiemeier (PI Psychiatric diseases), Andre´ Uitter-
linden (PI Genomic studies), and Meike Vernooij (PI
Population Imaging); and Jan Heeringa, MD, PhD, study
coordinator, Eric Neeleman, head IT, and Frank van Rooij,
MSc, head data-management.
Emeritus principal investigators
The following persons are Principal Investigator Emeritus
of the Rotterdam Study:
Frank van den Ouweland (PI Internal Medicine
1990–1992), Diederick Grobbee (PI Cardiovascular dis-
eases 1990–1996), Albert Hofman (PI Neurological dis-
eases 1990–1996), Paulus de Jong (PI Ophthalmic diseases
1990–2005), Huibert Pols (PI Internal Medicine
1993–2006), Monique Breteler (PI Neurological diseases
1997–2010), Gabriel Krestin (PI Population Imaging
1998–2010), Johannes Vingerling (PI Ophthalmic diseases
2005–2010), Jacqueline Witteman (PI Cardiovascular dis-
eases 1997–2011), Ernst Kuipers (PI Internal Medicine
2007–2013), Harry Janssen (PI Hepatic diseases
2007–2013).
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